Breast Neoplasms

• 

  Subject Areas on Research

  • "Choosing Wisely" in Breast Cancer Surgery: Drivers of Low Value Care. 
  • "Going Flat" After Mastectomy: Patient-Reported Outcomes by Online Survey. 
  • "If I'm better than average, then I'm ok?": Comparative information influences beliefs about risk and benefits. 
  • "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. 
  • "This is some mess right here": Exploring interactions between Black sexual minority women and health care providers for breast cancer screening and care. 
  • 'At All Costs': Breast Cancer Patient Responses to Cost Transparency and Communication. 
  • 'I'll do what they did": social norm information and cancer treatment decisions. 
  • (AI) Can't get off my chair. 
  • 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. 
  • 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. 
  • 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. 
  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 
  • 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. 
  • Four Conversations : A Randomized Controlled Trial of an Online, Personalized Coping and Decision Aid for Metastatic Breast Cancer Patients. 
  • A 35-Year Evolution of Free Flap-Based Breast Reconstruction at a Large Urban Academic Center. 
  • A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss. 
  • A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. 
  • A Case for Wide-Angle Breast Tomosynthesis. 
  • A Comparison of Complications in Therapeutic versus Contralateral Prophylactic Mastectomy Reconstruction: A Paired Analysis. 
  • A Comparison of Patient-Reported Outcomes in Bipedicled Total Abdominal versus Unipedicled Hemiabdominal Free Flaps for Unilateral Breast Reconstruction. 
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. 
  • A Comparison of Surgical Complications in Patients Undergoing Delayed versus Staged Tissue-Expander and Free-Flap Breast Reconstruction. 
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A Data Set and Deep Learning Algorithm for the Detection of Masses and Architectural Distortions in Digital Breast Tomosynthesis Images. 
  • A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo. 
  • A Flux Balance of Glucose Metabolism Clarifies the Requirements of the Warburg Effect. 
  • A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. 
  • A National Snapshot of Patient-Reported Outcomes Comparing Types of Abdominal Flaps for Breast Reconstruction. 
  • A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. 
  • A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). 
  • A Phase 2 study of perifosine in advanced or metastatic breast cancer. 
  • A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. 
  • A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. 
  • A Procedure for Eliciting Women's Preferences for Breast Cancer Screening Frequency. 
  • A Quantitative Diffuse Reflectance Imaging (QDRI) System for Comprehensive Surveillance of the Morphological Landscape in Breast Tumor Margins. 
  • A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. 
  • A SAGE (serial analysis of gene expression) view of breast tumor progression. 
  • A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. 
  • A bayesian analysis strategy for cross-study translation of gene expression biomarkers. 
  • A bivariate frailty model with a cure fraction for modeling familial correlations in diseases. 
  • A bivariate survival model with compound Poisson frailty. 
  • A brief intervention to enhance breast cancer clinicians' communication about sexual health: Feasibility, acceptability, and preliminary outcomes. 
  • A case of acute onset gigantomastia in a 20-year-old woman. 
  • A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma. 
  • A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. 
  • A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. 
  • A comparison of clinical and dosimetric outcomes in patients receiving partial breast irradiation with photon-only versus mixed photon/electron treatment plans. 
  • A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience. 
  • A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers. 
  • A comprehensive method for optical-emission computed tomography. 
  • A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. 
  • A correlated frailty model with long-term survivors for estimating the heritability of breast cancer. 
  • A couple-based intervention for female breast cancer. 
  • A cross-sectional study of anxiety and marital quality among women with breast cancer at a university clinic in western Saudi Arabia. 
  • A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. 
  • A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. 
  • A demonstration of ''less can be more'' in risk graphics. 
  • A desensitization protocol for the mAb cetuximab. 
  • A dual-emissive-materials design concept enables tumour hypoxia imaging. 
  • A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. 
  • A feasible and acceptable multicultural psychosocial intervention targeting symptom management in the context of advanced breast cancer. 
  • A finite element model of remote palpation of breast lesions using radiation force: factors affecting tissue displacement. 
  • A framework for improving early detection of breast cancer in sub-Saharan Africa: A qualitative study of help-seeking behaviors among Malawian women. 
  • A general formulation for a one-sided group sequential design. 
  • A generative adversarial network-based abnormality detection using only normal images for model training with application to digital breast tomosynthesis. 
  • A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. 
  • A home-based mentored vegetable gardening intervention demonstrates feasibility and improvements in physical activity and performance among breast cancer survivors. 
  • A joint analysis of metabolomics and genetics of breast cancer. 
  • A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. 
  • A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. 
  • A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. 
  • A mathematical model platform for optimizing a multiprojection breast imaging system. 
  • A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. 
  • A multi-modal exploration of heterogeneous physico-chemical properties of DCIS breast microcalcifications. 
  • A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. 
  • A national snapshot of satisfaction with breast cancer procedures. 
  • A network of genetic events sufficient to convert normal human cells to a tumorigenic state. 
  • A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. 
  • A neural network approach to breast cancer diagnosis as a constraint satisfaction problem. 
  • A neural network to predict symptomatic lung injury. 
  • A neural survival factor is a candidate oncogene in breast cancer. 
  • A new method to accurately identify single nucleotide variants using small FFPE breast samples. 
  • A new permutation-based method for assessing agreement between two observers making replicated binary readings. 
  • A nonparametric empirical Bayes framework for large-scale multiple testing 
  • A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. 
  • A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. 
  • A novel approach to sensory re-innervation to the nipple areolar complex after mastectomy with implant-based reconstruction: Anatomic and technical considerations. 
  • A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A novel ultrasonic technique for differentiating cysts from solid lesions: preliminary results in the breast. 
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials. 
  • A pathway-based classification of human breast cancer. 
  • A phase 1 trial of preoperative partial breast radiation therapy: Patient selection, target delineation, and dose delivery. 
  • A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. 
  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 
  • A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. 
  • A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. 
  • A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. 
  • A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. 
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. 
  • A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. 
  • A pilot study of a home-based motivational exercise program for African American breast cancer survivors: clinical and quality-of-life outcomes. 
  • A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. 
  • A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. 
  • A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. 
  • A polycyclic aromatic hydrocarbon-enriched environmental chemical mixture enhances AhR, antiapoptotic signaling and a proliferative phenotype in breast cancer cells. 
  • A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A preliminary study of the role of modulated electron beams in intensity modulated radiotherapy, using automated beam orientation and modality selection. 
  • A procedure for obtaining impact of cancer version 2 scores using version 1 responses. 
  • A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. 
  • A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. 
  • A prospective randomized, placebo-controlled skin care study in women diagnosed with breast cancer undergoing radiation therapy. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. 
  • A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. 
  • A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. 
  • A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors. 
  • A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. 
  • A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. 
  • A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial. 
  • A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. 
  • A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. 
  • A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. 
  • A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. 
  • A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. 
  • A review of hereditary breast cancer: from screening to risk factor modification. 
  • A robust method for estimating optimal treatment regimes. 
  • A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. 
  • A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. 
  • A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models. 
  • A study on the computerized fractal analysis of architectural distortion in screening mammograms. 
  • A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. 
  • A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. 
  • A systems biology view of cancer. 
  • A tailored intervention to aid decision-making about hormone replacement therapy. 
  • A two-disease model of female breast cancer: mortality in 1969 among white females in the United States. 
  • A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. 
  • A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing. 
  • AAAPT Diagnostic Criteria for Acute Pain Following Breast Surgery. 
  • ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. 
  • ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. 
  • ACR Appropriateness Criteria® Transgender Breast Cancer Screening. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • AIUM practice guideline for the performance of a breast ultrasound examination. 
  • AJR teaching file: incidental breast cancer detected with 18F-FDG PET/CT. 
  • AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. 
  • APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. 
  • ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. 
  • ASO Author Reflections: Decision Support Tools Are Needed to Address Dissatisfaction Among Women Seeking Post-Mastectomy Breast Reconstruction. 
  • ASO Author Reflections: Entering the Era of Biomarker-Driven Management of the Axilla. 
  • ASO Author Reflections: Molecular Signatures May Render Surgical Staging of the Axilla Obsolete. 
  • ASO Author Reflections: Moving the Ball Forward Toward De-Escalation of Axillary Surgery for Patients with Clinically Node-Positive Disease. 
  • ASO Author Reflections: Optimal Timing of Autologous Breast Reconstruction Should Incorporate Patient Perspectives When Balancing the Increased Risks of a Staged Approach. 
  • ASO Visual Abstract: "Going Flat" After Mastectomy: Patient-Reported Outcomes by Online Survey. 
  • ASO Visual Abstract: Complications, Costs, and Healthcare Resource Utilization After Staged, Delayed, and Immediate Free-Flap Breast Reconstruction-A Longitudinal, Claims-Based Analysis. 
  • ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). 
  • ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. 
  • ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. 
  • ASO Visual Abstract: Margin Management and Adjuvant Therapy for Phyllodes Tumors-Practice Patterns of the American Society of Breast Surgeons Members. 
  • ASO Visual Abstract: Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer. 
  • ASO Visual Abstract: Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. 
  • Abbreviated screening protocol for breast MRI: a feasibility study. 
  • Abdominal obesity and breast cancer risk. 
  • Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. 
  • Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. 
  • Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. 
  • Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. 
  • Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect. 
  • Accelerated partial breast irradiation after conservative surgery for breast cancer. 
  • Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). 
  • Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). 
  • Accelerated partial breast irradiation: caution and concern from an ASTRO task force. 
  • Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. 
  • Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. 
  • Accuracy of Predictions of Patients With Breast Cancer of Future Well-being After Immediate Breast Reconstruction. 
  • Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. 
  • Accuracy of segmentation of a commercial computer-aided detection system for mammography. 
  • Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. 
  • Accurate Inputs for Costs and Benefits of Screening Mammography. 
  • Acoustic radiation force elasticity imaging in diagnostic ultrasound. 
  • Acoustic separation of circulating tumor cells. 
  • Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. 
  • Acquisition of metastatic tissue from patients with bone metastases from breast cancer. 
  • Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. 
  • Active Breathing Coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: report of a prospective trial. 
  • Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring. 
  • Activity of a Py-Im polyamide targeted to the estrogen response element. 
  • Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. 
  • Adapting a couple-based intimacy enhancement intervention to breast cancer: A developmental study. 
  • Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. 
  • Additive estrogenic activities of a binary mixture of 2',4',6'-trichloro- and 2',3',4',5'-tetrachloro-4-biphenylol. 
  • Addressing Disparities Related to Access of Multimodality Breast Imaging Services Before and During the COVID-19 Pandemic. 
  • Adenoid cystic carcinoma of the breast metastatic to the kidney. A clinically symptomatic lesion requiring surgical management. 
  • Adenosquamous differentiation: mammary needle aspiration cytology. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. 
  • Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. 
  • Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 
  • Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. 
  • Adherence to cardiovascular disease risk factor medications among patients with cancer: a systematic review. 
  • Adherence to quality indicators and survival in patients with breast cancer. 
  • Adipocyte mesenchymal transition contributes to mammary tumor progression. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making. 
  • Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. 
  • Adjuvant hormonal therapy use among insured, low-income women with breast cancer. 
  • Adjuvant hormonal therapy use among women with ductal carcinoma in situ. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Adolescent reproductive events and subsequent breast cancer risk. 
  • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. 
  • Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. 
  • Adult cancer survivors discuss follow-up in primary care: 'not what i want, but maybe what i need'. 
  • Advanced imaging and hospice use in end-of-life cancer care. 
  • Advances and current concepts in reconstructive surgery for breast cancer. 
  • Advances in quantitative UV-visible spectroscopy for clinical and pre-clinical application in cancer. 
  • Advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast. 
  • Advancing the science of mind-body interventions: a comment on Larkey et al. 
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 
  • Adverse health outcomes in women exposed in utero to diethylstilbestrol. 
  • African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. 
  • Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. 
  • Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. 
  • Age at diagnosis and multiple primary cancers of the breast and ovary. 
  • Age at menarche, time to regular cycling, and breast cancer (North Carolina, United States). 
  • Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. 
  • Aging and neoplasia. 
  • Agreement between a brief mailed screener and an in-depth telephone survey: observations from the Fresh Start study. 
  • Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. 
  • Alcohol consumption and breast cancer among black and white women in North Carolina (United States). 
  • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 
  • All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. 
  • Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation. 
  • Altered TGF-α/β signaling drives cooperation between breast cancer cell populations. 
  • Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. 
  • Ambulatory surgical management of breast carcinoma using paravertebral block. 
  • American College of Surgeons Oncology Group and the community surgeon. 
  • American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. 
  • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. 
  • Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. 
  • An Assessment of Patient Satisfaction and Decisional Regret in Patients Undergoing Staged Free-Flap Breast Reconstruction. 
  • An EXITS strategy for decreasing cancer risk in women. 
  • An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients. 
  • An Engineered Tumor-on-a-Chip Device with Breast Cancer-Immune Cell Interactions for Assessing T-cell Recruitment. 
  • An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. 
  • An adaptive incremental approach to constructing ensemble classifiers: application in an information-theoretic computer-aided decision system for detection of masses in mammograms. 
  • An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. 
  • An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. 
  • An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. 
  • An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. 
  • An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. 
  • An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. 
  • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. 
  • An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. 
  • An unusual cause of cholecystitis? 
  • Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. 
  • Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database. 
  • Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. 
  • Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. 
  • Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. 
  • Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. 
  • Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. 
  • Anatomic Targets for Breast Reconstruction Neurotization: Past Results and Future Possibilities. 
  • Anatomy and Breast Cancer Staging: Is It Still Relevant? 
  • Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma. 
  • Aneuploid subpopulations in tumour-invaded lymph nodes from breast cancer patients. 
  • Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. 
  • Anomalous azygous-hemiazygous anastomosis: radiographic findings. 
  • Anomaly Detection of Calcifications in Mammography Based on 11,000 Negative Cases. 
  • Another round in the mammography controversy. 
  • Antemortem diagnosis of an endomyocardial breast cancer metastasis by transvenous endomyocardial biopsy. 
  • Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review. 
  • Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. 
  • Antibody reacting with mouse mammary tumor virus in serum of breast carcinoma patients. 
  • Antibody-based biosensor for breast cancer with ultrasonic regeneration. 
  • Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. 
  • Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 
  • Anticancer therapeutic potential of Mn porphyrin/ascorbate system. 
  • Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. 
  • Antigen retrieval, blocking, detection and visualisation systems in immunohistochemistry: a review and practical evaluation of tyramide and rolling circle amplification systems. 
  • Antimetastatic potential of PAI-1-specific RNA aptamers. 
  • Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. 
  • Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. 
  • Anxiety prior to breast biopsy: Relationships with length of time from breast biopsy recommendation to biopsy procedure and psychosocial factors. 
  • Application of likelihood ratio to classification of mammographic masses; performance comparison to case-based reasoning. 
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. 
  • Applying the Rapid OPPERA Algorithm to Predict Persistent Pain Outcomes Among a Cohort of Women Undergoing Breast Cancer Surgery. 
  • Applying the neoadjuvant paradigm to ductal carcinoma in situ. 
  • Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. 
  • Appropriate design of prospective studies. 
  • Architectural Distortion on Mammography: Correlation With Pathologic Outcomes and Predictors of Malignancy. 
  • Are all aromatase inhibitors alike? 
  • Are we choosing wisely? Drivers of preoperative MRI use in breast cancer patients. 
  • Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804. 
  • Aromatase Inhibitor Symptom Management Practices: A Retrospective Study. 
  • Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. 
  • Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York. 
  • Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. 
  • Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. 
  • Artificial neural network: improving the quality of breast biopsy recommendations. 
  • Artificial neural networks improve the accuracy of cancer survival prediction. 
  • Assessing observer agreement in studies involving replicated binary observations. 
  • Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study). 
  • Assessing the Burden of Nodal Disease for Breast Cancer Patients with Clinically Positive Nodes: Hope for More Limited Axillary Surgery. 
  • Assessing the Influence of Failed Implant Reconstruction on Patient Satisfaction and Decision Regret after Salvage Free-Flap Breast Reconstruction. 
  • Assessing the Relationship between Anxiety and Revision Surgery following Autologous Breast Reconstruction. 
  • Assessing the Utility of Post-Mastectomy Imaging after Breast Reconstruction. 
  • Assessing the risk of breast cancer. 
  • Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. 
  • Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy: Initial Results. 
  • Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. 
  • Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. 
  • Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay. 
  • Assessment of task-based performance from five clinical DBT systems using an anthropomorphic breast phantom. 
  • Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. 
  • Assessment of the residual error in soft tissue setup in patients undergoing partial breast irradiation: results of a prospective study using cone-beam computed tomography. 
  • Associating persistent self-reported cognitive decline with neurocognitive decline in older breast cancer survivors using machine learning: The Thinking and Living with Cancer study. 
  • Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures. 
  • Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China. 
  • Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. 
  • Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. 
  • Association between KRAS rs61764370 and triple-negative breast cancer--a false positive? 
  • Association between breast cancer and allostatic load by race: National Health and Nutrition Examination Survey 1999-2008. 
  • Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. 
  • Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. 
  • Association between endometriosis and gynecological cancers: a critical review of the literature. 
  • Association between family history of prostate and breast cancer among African-American men with prostate cancer. 
  • Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. 
  • Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 
  • Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. 
  • Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. 
  • Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis. 
  • Association between reproductive factors and breast cancer survival in younger women. 
  • Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults. 
  • Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. 
  • Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study. 
  • Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer. 
  • Association of Life-Course Educational Attainment and Breast Cancer Grade in the MEND Study. 
  • Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. 
  • Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype. 
  • Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. 
  • Association of Uveitis and Macular Edema With Anastrozole Therapy. 
  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study. 
  • Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. 
  • Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. 
  • Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer. 
  • Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. 
  • Association of genetic variants of FBXO32 and FOXO6 in the FOXO pathway with breast cancer risk. 
  • Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. 
  • Association of lipid profile biomarkers with breast cancer by molecular subtype: analysis of the MEND study. 
  • Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study. 
  • Association of maternal and intrauterine characteristics with age at menarche in a multiethnic population in Hawaii. 
  • Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. 
  • Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. 
  • Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis. 
  • Associations Between Catecholaminergic and Serotonergic Genes and Persistent Arm Pain Severity Following Breast Cancer Surgery. 
  • Associations Between Catecholaminergic and Serotonergic Genes and Persistent Breast Pain Phenotypes After Breast Cancer Surgery. 
  • Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. 
  • Associations between Personal Care Product Use Patterns and Breast Cancer Risk among White and Black Women in the Sister Study. 
  • Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. 
  • Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. 
  • Associations between longitudinal changes in sleep disturbance and depressive and anxiety symptoms during the COVID-19 virus pandemic among older women with and without breast cancer in the thinking and living with breast cancer study. 
  • Associations of Premenopausal Hysterectomy and Oophorectomy With Breast Cancer Among Black and White Women: The Carolina Breast Cancer Study, 1993-2001. 
  • Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. 
  • Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. 
  • Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. 
  • Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. 
  • Atypical hyperplasia: frequency and mammographic and pathologic relationships in excisional biopsies guided with mammography and clinical examination. 
  • Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. 
  • Autofluorescence and diffuse reflectance properties of malignant and benign breast tissues. 
  • Autofluorescence spectroscopy of normal and malignant human breast cell lines. 
  • Automated breast mass detection in 3D reconstructed tomosynthesis volumes: a featureless approach. 
  • Automated measurement of microcirculatory blood flow velocity in pulmonary metastases of rats. 
  • Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. 
  • Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. 
  • Axillary adenopathy detected on breast MRI following COVID-19 vaccination: outcomes and follow-up recommendations. 
  • Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough? 
  • Axillary lymph node dissection versus the sentinel lymph node technique in breast cancer. 
  • Axillary lymph nodes: mammographic, pathologic, and clinical correlation. 
  • Axillary reverse mapping and lymphaticovenous bypass: Lymphedema prevention through enhanced lymphatic visualization and restoration of flow. 
  • BI-RADS categorization as a predictor of malignancy. 
  • BI-RADS for sonography: positive and negative predictive values of sonographic features. 
  • BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway. 
  • BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. 
  • BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. 
  • BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. 
  • BRCA1 expression is not directly responsive to estrogen. 
  • BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. 
  • BRCA1 mutations in primary breast and ovarian carcinomas. 
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. 
  • BRCA2 monoclonal antibodies react with differentiating epithelium. 
  • BRCA2 mutations in primary breast and ovarian cancers. 
  • BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. 
  • Barriers reported among patients with breast and cervical abnormalities in the patient navigation research program: impact on timely care. 
  • Barriers to Breast and Cervical Cancer Screening in Singapore: a Mixed Methods Analysis. 
  • Barriers to clinical trial participation by older women with breast cancer. 
  • Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program. 
  • Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. 
  • Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. 
  • Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. 
  • Behavioral cancer pain intervention using videoconferencing and a mobile application for medically underserved patients: Rationale, design, and methods of a prospective multisite randomized controlled trial. 
  • Behavioral consequences of conflict-oriented health news coverage: the 2009 mammography guideline controversy and online information seeking. 
  • Belief in numbers: When and why women disbelieve tailored breast cancer risk statistics. 
  • Beliefs about breast cancer risk and use of postmenopausal hormone replacement therapy. 
  • Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. 
  • Benefits and Harms of Breast Cancer Screening: A Systematic Review. 
  • Benefits and Risks of Mammography Screening in Women Ages 40 to 49 Years. 
  • Benefits and drawbacks to hormone replacement therapy among nursing home patients. 
  • Benefits from an uncertainty management intervention for African-American and Caucasian older long-term breast cancer survivors. 
  • Benefits of the uncertainty management intervention for African American and White older breast cancer survivors: 20-month outcomes. 
  • Benign breast disease: when to treat, when to reassure, when to refer. 
  • Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. 
  • Beyond Black and White: race and sexual identity as contributors to healthcare system distrust after breast cancer screening among US women. 
  • Beyond Mirels: Factors Influencing Surgical Outcome of Metastasis to the Extremities in the Modern Era. 
  • Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. 
  • Bilateral Diffuse Pseudoangiomatous Stromal Hyperplasia Necessitating Mastectomy. 
  • Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. 
  • Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. 
  • Bioavailability of estradiol as a marker for breast cancer risk assessment. 
  • Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. 
  • Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. 
  • Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. 
  • Birth weight and breast cancer risk. 
  • Bisphosphonate-associated arthritis. 
  • Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism. 
  • Bleeding After Free Flap-Based Breast Reconstruction: A NSQIP Analysis. 
  • Body composition and bone mineral density in breast cancer survivors and non-cancer controls: A 12- to 15-month follow-up. 
  • Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors. 
  • Body size across the life course and risk of premenopausal and postmenopausal breast cancer in Black women, the Carolina Breast Cancer Study, 1993-2001. 
  • Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. 
  • Bone metastases from breast cancer: value of CT bone windows. 
  • Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. 
  • Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively. 
  • Brain metastases in breast cancer. 
  • Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies. 
  • Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. 
  • Breast Cancer Radiogenomics: Current Status and Future Directions. 
  • Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. 
  • Breast Cancer Risk-Reducing Medications. 
  • Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. 
  • Breast Cancer Screening and Care Among Black Sexual Minority Women: A Scoping Review of the Literature from 1990 to 2017. 
  • Breast Cancer Screening and Health Care Costs. 
  • Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. 
  • Breast Cancer Screening: Benefit or Harm?--Reply. 
  • Breast Cancer Version 2.2015. 
  • Breast Cancer after Augmentation: Oncologic and Reconstructive Considerations among Women Undergoing Mastectomy. 
  • Breast Cancer and Reconstruction: Normative Data for Interpreting the BREAST-Q. 
  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast Cancer-Related Employment Disruption and Financial Hardship in the Sister Study. 
  • Breast Imaging for Transgender Individuals: Assessment of Current Practice and Needs. 
  • Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Updated Systematic Review and Analysis of Treatment Strategies. 
  • Breast MRI as an adjunct in the diagnosis of a carcinoma partially obscured on mammography. 
  • Breast MRI biopsy cancellation due to lesion nonvisualization. 
  • Breast MRI radiogenomics: Current status and research implications. 
  • Breast US: assessment of technical quality and image interpretation. 
  • Breast and ovarian cancer in the older woman. 
  • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. 
  • Breast biopsy in women 30 years old or less. 
  • Breast biopsy: a comparative study of stereotaxically guided core and excisional techniques. 
  • Breast cancer MRI radiomics: An overview of algorithmic features and impact of inter-reader variability in annotating tumors. 
  • Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. 
  • Breast cancer after chest radiation therapy for childhood cancer. 
  • Breast cancer aggressiveness and racial disparity. 
  • Breast cancer and aging. Clinical interactions. 
  • Breast cancer and aging: Standing on the shoulders of a giant. 
  • Breast cancer and aging: results of the U13 conference breast cancer panel. 
  • Breast cancer and dietary factors in Taiwanese women. 
  • Breast cancer and estrogen replacement therapy. 
  • Breast cancer anxiety's associations with responses to a chemoprevention decision aid. 
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. 
  • Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition? 
  • Breast cancer deaths averted over 3 decades. 
  • Breast cancer detection using high-density flexible electrode arrays and electrical impedance tomography. 
  • Breast cancer following spinal irradiation for a childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. 
  • Breast cancer in older patients. 
  • Breast cancer in older women. 
  • Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. 
  • Breast cancer in the elderly. Current patterns of care. 
  • Breast cancer in women under 35 years of age. 
  • Breast cancer in young women: Imaging and clinical course. 
  • Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. 
  • Breast cancer of the older woman: an annotated review. 
  • Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. 
  • Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. 
  • Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy. 
  • Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview. 
  • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. 
  • Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. 
  • Breast cancer screening and diagnosis. 
  • Breast cancer screening behaviors and attitudes in three racial/ethnic groups. 
  • Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. 
  • Breast cancer screening in older women: practices and barriers reported by primary care physicians. 
  • Breast cancer screening in older women: the geriatrician/internist perspective. 
  • Breast cancer screening in women exposed in utero to diethylstilbestrol. 
  • Breast cancer screening with mammography. 
  • Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? 
  • Breast cancer screening-individualized risk assessment and application of new research technology: non-protein bound estradiol and chromosome analysis. 
  • Breast cancer screening: science, society and common sense. 
  • Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. 
  • Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. 
  • Breast cancer survival in African-American women by hormone receptor subtypes. 
  • Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. 
  • Breast cancer version 3.2014. 
  • Breast cancer, version 3.2013: featured updates to the NCCN guidelines. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Breast cancer: hormones and other risk factors. 
  • Breast cancer: integrating the patient with her genome. 
  • Breast cancer: noninvasive and special situations. 
  • Breast cancer: prediction with artificial neural network based on BI-RADS standardized lexicon. 
  • Breast carcinoma masquerading as primary ovarian neoplasm. 
  • Breast carcinoma, thyroid carcinoma, and T3 thyrotoxicosis in a male cretin. 
  • Breast carcinoma: MR imaging before re-excisional biopsy. 
  • Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? 
  • Breast conservation rates-barriers between tertiary care and community practice. 
  • Breast conservation surgery using nipple-areolar resection for central breast cancers. 
  • Breast conservation: is the survival better for mastectomy? 
  • Breast imaging reporting and data system standardized mammography lexicon: observer variability in lesion description. 
  • Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. 
  • Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. 
  • Breast lidocaine priming for improved mastectomy survival. 
  • Breast mass lesions: computer-aided diagnosis models with mammographic and sonographic descriptors. 
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. 
  • Breast papillomas in the era of percutaneous needle biopsy. 
  • Breast reconstruction following mastectomy. 
  • Breast reconstruction following subcutaneous mastectomy for cancer: a critical appraisal of the nipple-areola complex. 
  • Breast self-examination: defining a cohort still in need. 
  • Breast sensorisexual function: a novel patient-reported outcome measure of sexual sensory functions of the breast. 
  • Breast skin calcifications: localization with a stereotactic device. 
  • Breast tomosynthesis: state-of-the-art and review of the literature. 
  • Breast tumour imaging using incomplete circular orbit pinhole SPET: a phantom study. 
  • Breast-feeding with ectopic axillary breast tissue. 
  • Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. 
  • Building a predictive breast cancer risk model. 
  • C- and D-weighted ultrasonic imaging using the translating apertures algorithm. 
  • CACNG2 polymorphisms associate with chronic pain after mastectomy. 
  • CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. 
  • CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. 
  • CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. 
  • CDK4/6 inhibitors in breast cancer. 
  • CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. 
  • CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers. 
  • CK1epsilon is required for breast cancers dependent on beta-catenin activity. 
  • COVID-19 Vaccine-Related Axillary Adenopathy on Breast Imaging: Follow-Up Recommendations and Histopathologic Findings. 
  • COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. 
  • CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • CT of pectoralis muscle invasion by breast carcinoma. 
  • CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. 
  • CT-guided hookwire placement: a technical innovation for preoperative localization of nonpalpable cervical lymph nodes. 
  • CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. 
  • CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. 
  • Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. 
  • Camptothecin analogues with enhanced antitumor activity at acidic pH. 
  • Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features? 
  • Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? 
  • Can breast cancer molecular subtype help to select patients for preoperative MR imaging? 
  • Can compression be reduced for breast tomosynthesis? Monte carlo study on mass and microcalcification conspicuity in tomosynthesis. 
  • Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. 
  • Can screening older patients for cancer save lives? 
  • Can underpowered clinical trials be justified? 
  • Cancelation of MRI guided breast biopsies for suspicious breast lesions identified at 3.0 T MRI: reasons, rates, and outcomes. 
  • Cancer Outcomes in DCIS Patients Without Locoregional Treatment. 
  • Cancer Screening Results and Follow-up Using Routinely Collected Electronic Health Data: Estimates for Breast, Colon, and Cervical Cancer Screenings. 
  • Cancer Survivorship Program: Implementation for Individuals With Recurrent Breast Cancer. 
  • Cancer and pregnancy: the clinician's perspective. 
  • Cancer cases from ACRIN digital mammographic imaging screening trial: radiologist analysis with use of a logistic regression model. 
  • Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies. 
  • Cancer genetics service interest in women with a limited family history of breast cancer. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Cancer screening before and after switching to a high-deductible health plan. 
  • Cancer screening behaviors and attitudes of women in southeastern Minnesota. 
  • Cancer screening practices among women in a community health center population. 
  • Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804. 
  • Cancer survivors' health worries and associations with lifestyle practices. 
  • Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training. 
  • Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. 
  • Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. 
  • Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. 
  • Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. 
  • Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Carcinocythemia (carcinoma cell leukemia). 
  • Cardiac Morbidity and Radiation Therapy for Breast Cancer. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. 
  • Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. 
  • Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. 
  • Cardiorespiratory fitness in breast cancer patients: a call for normative values. 
  • Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. 
  • Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. 
  • Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. 
  • Cardiovascular complications of breast cancer therapy in older adults. 
  • Caregiver Characteristics Associated With Cognitive Complaints in Women With Breast Cancer. 
  • Caring for breast cancer survivors in primary care. 
  • Case-based reasoning computer algorithm that uses mammographic findings for breast biopsy decisions. 
  • Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. 
  • Catechol-O-methyltransferase and breast cancer risk. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Cell cycle control of BRCA2. 
  • Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. 
  • Cell dissociation techniques in human breast cancer--variations in tumor cell viability and DNA ploidy. 
  • Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor. 
  • Cellular senescence: from anti-cancer weapon to anti-aging target. 
  • Cellular uptake and photodynamic activity of protein nanocages containing methylene blue photosensitizing drug. 
  • Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Change in self-efficacy partially mediates the effects of the FRESH START intervention on cancer survivors' dietary outcomes. 
  • Changes in diet and physical activity following BRCA1/2 testing. 
  • Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act. 
  • Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. 
  • Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. 
  • Characterization of BRCA1 and BRCA2 mutations in a large United States sample. 
  • Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. 
  • Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women. 
  • Characterizing the impact of 25 years of DCIS treatment. 
  • Check the Record: Remote CT Scans for Breast Flap Perforator Mapping. 
  • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. 
  • Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. 
  • Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. 
  • Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Cholesterol and breast cancer pathophysiology. 
  • Cholesterol granuloma of the breast mimicking carcinoma: report of a case. 
  • Choosing wisely: the American Society for Radiation Oncology's top 5 list. 
  • Chromatographic analysis and decomposition product characterization of compound SR16157 (NSC 732011). 
  • Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. 
  • Cigarette smoking and the risk of female reproductive cancer. 
  • Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. 
  • Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States). 
  • CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. 
  • Circadian disruption--a new direction for psycho-oncology research? A comment on Dedert et al. 
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. 
  • Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. 
  • Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. 
  • Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us. 
  • Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. 
  • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. 
  • Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. 
  • Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. 
  • Clinical Breast Examination and Breast Cancer Screening Guideline--Reply. 
  • Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. 
  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. 
  • Clinical Impact of ASCO Choosing Wisely Guidelines on Staging Imaging for Early-Stage Breast Cancers: A Time Series Analysis Using SEER-Medicare Data. 
  • Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. 
  • Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Clinical and pathological stage discordance among 433,514 breast cancer patients. 
  • Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. 
  • Clinical applications of PET in oncology. 
  • Clinical characteristics of patients with cancer referred for outpatient physical therapy. 
  • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. 
  • Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Clinical validation of a customized multiple signature microarray for breast cancer. 
  • Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. 
  • Clinically relevant changes in family history of cancer over time. 
  • Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. 
  • Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. 
  • Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Co-expression of urokinase with haptoglobin in human carcinomas. 
  • Co-occurring Fatigue and Lymphatic Pain Incrementally Aggravate Their Negative Effects on Activities of Daily Living, Emotional Distress, and Overall Health of Breast Cancer Patients. 
  • Cognitive errors and logistical breakdowns contributing to missed and delayed diagnoses of breast and colorectal cancers: a process analysis of closed malpractice claims. 
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). 
  • Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. 
  • Cognitive function prior to systemic therapy and subsequent well-being in older breast cancer survivors: Longitudinal findings from the Thinking and Living with Cancer Study. 
  • Collaboration between breast and reconstructive surgery in optimizing outcomes for women with breast cancer. 
  • Collaboration between the breast and plastic surgeon in restoring sensation after mastectomy. 
  • Collaborative Molecular Epidemiology Study of Metabolic Dysregulation, DNA Methylation, and Breast Cancer Risk Among Nigerian Women: MEND Study Objectives and Design. 
  • Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis. 
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. 
  • Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. 
  • Combination of flavor enhancement and chemosensory education improves nutritional status in older cancer patients. 
  • Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma. 
  • Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. 
  • Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. 
  • Comment on "Surgical Delay in Nipple-sparing Mastectomy". 
  • Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. 
  • Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis. 
  • Communicating breast cancer risks to women using different formats. 
  • Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs. 
  • Communication factors in the follow-up of abnormal mammograms. 
  • Community collaboration to improve access and outcomes in breast cancer reconstruction: protocol for a mixed-methods qualitative research study. 
  • Community- and individual-level socioeconomic status and breast cancer risk: multilevel modeling on Cape Cod, Massachusetts. 
  • Comorbidity burden and guideline-concordant care for breast cancer. 
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). 
  • Comparative analyses of mechanistic differences among antiestrogens. 
  • Comparative analysis of breast cancer risk factors among African-American women and White women. 
  • Comparative analysis of instance selection algorithms for instance-based classifiers in the context of medical decision support. 
  • Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. 
  • Comparative performance of multiview stereoscopic and mammographic display modalities for breast lesion detection. 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy. 
  • Comparing digital tomosynthesis to cone-beam CT for position verification in patients undergoing partial breast irradiation. 
  • Comparing the value of mammographic features and genetic variants in breast cancer risk prediction. 
  • Comparison of 3D conformal breast radiation treatment plans using the anisotropic analytical algorithm and pencil beam convolution algorithm. 
  • Comparison of Diagnostic Mammography-Guided Biopsy and Digital Breast Tomosynthesis-Guided Biopsy of Suspicious Breast Calcifications: Results in 1354 Biopsies. 
  • Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. 
  • Comparison of LCD and CRT displays based on efficacy for digital mammography. 
  • Comparison of Outcomes for One-View Asymmetries Recalled From Digital Breast Tomosynthesis Versus Full-Field Digital Mammography Screening Examinations. 
  • Comparison of Reconstructive Outcomes in Breast Cancer Patients With Preexisting Subpectoral Implants: Implant-Sparing Mastectomy With Delayed Implant Exchange Versus Immediate Tissue Expander Reconstruction. 
  • Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. 
  • Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. 
  • Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach. 
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). 
  • Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. 
  • Comparison of multiexcitation fluorescence and diffuse reflectance spectroscopy for the diagnosis of breast cancer (March 2003). 
  • Comparison of recall and cancer detection rates for immediate versus batch interpretation of screening mammograms. 
  • Comparison of three concomitant boost techniques for early-stage breast cancer. 
  • Comparison of unenhanced, hepatic arterial-dominant, and portal venous-dominant phase helical CT for the detection of liver metastases in women with breast carcinoma. 
  • Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. 
  • Complex response of breast epithelial cell lines to topoisomerase inhibitors. 
  • Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance. 
  • Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. 
  • Complications, Costs, and Healthcare Resource Utilization After Staged, Delayed, and Immediate Free-Flap Breast Reconstruction: A Longitudinal, Claims-Based Analysis. 
  • Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. 
  • Comprehensive Word-Level Classification of Screening Mammography Reports Using a Neural Network Sequence Labeling Approach. 
  • Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. 
  • Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. 
  • Comprehensive molecular portraits of human breast tumours. 
  • Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. 
  • Compromised HOXA5 function can limit p53 expression in human breast tumours. 
  • Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. 
  • Computer aided detection of masses in mammography using subregion Hotelling observers. 
  • Computer-aided classification of breast masses: performance and interobserver variability of expert radiologists versus residents. 
  • Computer-aided detection in screening mammography: variability in cues. 
  • Computer-aided detection of amorphous calcifications. 
  • Computer-aided diagnosis of breast cancer: artificial neural network approach for optimized merging of mammographic features. 
  • Computer-assisted detection of mammographic masses: a template matching scheme based on mutual information. 
  • Computerized detection of masses in digital mammograms: analysis of bilateral subtraction images. 
  • Computerized detection of masses in digital mammograms: automated alignment of breast images and its effect on bilateral-subtraction technique. 
  • Computerized detection of masses in digital mammograms: investigation of feature-analysis techniques. 
  • Computerized prompts for cancer screening in a community health center. 
  • Concordant, non-atypical breast papillomas do not require surgical excision: A 10-year multi-institution study and review of the literature. 
  • Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer. 
  • Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. 
  • Conformal microwave array (CMA) applicators for hyperthermia of diffuse chest wall recurrence. 
  • Confusion about mammography: prevalence and consequences. 
  • Congenital breast deformities: Anatomical basis and surgical approaches for optimal aesthetic outcomes. 
  • Congressional update: Report from the Biomedical Imaging Program of the National Cancer Institute. American College of Radiology Imaging Network: The digital mammographic imaging screening trial--an update. 
  • Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. 
  • Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. 
  • Consortium analysis of 7 candidate SNPs for ovarian cancer. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. 
  • Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. 
  • Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. 
  • Consumption of dairy products and the risk of breast cancer: a review of the literature. 
  • Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines. 
  • Contemporary management of ductal carcinoma in situ and lobular carcinoma in situ. 
  • Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. 
  • Continuous somatosensory evoked potential monitoring during brain tumor resection. Report of four cases and review of the literature. 
  • Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer? 
  • Contralateral Prophylactic Mastectomy: Aligning Patient Preferences and Provider Recommendations. 
  • Contribution of cancer symptoms, dysfunctional sleep related thoughts, and sleep inhibitory behaviors to the insomnia process in breast cancer survivors: a daily process analysis. 
  • Controlled aspiration of subretinal fluid in the diagnosis of carcinoma metastatic to the choroid. 
  • Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. 
  • Controversies in Breast Cancer Screening Strategies. 
  • Coping with genetic testing for breast cancer susceptibility. 
  • Coping with sexual concerns after cancer: the use of flexible coping. 
  • Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. 
  • Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study. 
  • Correlation of breast tissue histology and optical signatures to improve margin assessment techniques. 
  • Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. 
  • Cortisol levels and responses to mammography screening in breast cancer survivors: a pilot study. 
  • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. 
  • Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. 
  • Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. 
  • Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. 
  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. 
  • Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. 
  • Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. 
  • Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening. 
  • Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. 
  • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. 
  • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. 
  • Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. 
  • County-level cumulative environmental quality associated with cancer incidence. 
  • Couples and breast cancer: women's mood and partners' marital satisfaction predicting support perception. 
  • Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. 
  • Creating value in health by understanding and overcoming resistance to de-innovation. 
  • Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. 
  • Critical pathway for administering high-dose chemotherapy followed by peripheral blood stem cell rescue in the outpatient setting. 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Cross-institutional evaluation of BI-RADS predictive model for mammographic diagnosis of breast cancer. 
  • Cross-phase modulation imaging 
  • Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. 
  • Cross-study projections of genomic biomarkers: an evaluation in cancer genomics. 
  • Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro. 
  • Cross-validation for linear model with unequal variances in genomic analysis. 
  • Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold. 
  • Current Trends in the Management of Ductal Carcinoma In Situ. 
  • Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. 
  • Current and future cancer staging after neoadjuvant treatment for solid tumors. 
  • Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. 
  • Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. 
  • Current status of endocrine therapy for metastatic breast cancer. 
  • Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. 
  • Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. 
  • Cystosarcoma phylloides. A steroid receptor and ultrastructure analysis. 
  • Cytochemistry of sex steroid receptors: a critique. 
  • Cytokine Gene Polymorphisms Associated With Symptom Clusters in Oncology Patients Undergoing Radiation Therapy. 
  • Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. 
  • Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome. 
  • Cytologic findings in a case of postirradiation angiosarcoma of the breast. 
  • Cytologic studies of glucose-6-phosphate dehydrogenase in malignancy. 
  • Cytologically low grade malignancies: an important interpretative pitfall responsible for false negative diagnoses in fine-needle aspiration of the breast. 
  • Cytomegalovirus encephalomyelitis: MR imaging findings documenting response to ganciclovir therapy. 
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. 
  • DCIS with Microinvasion: Is It In Situ or Invasive Disease? 
  • DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway. 
  • DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. 
  • Daughters and Mothers Against Breast Cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters. 
  • De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. 
  • Decline in Racial Disparities in Postmastectomy Breast Reconstruction: A Surveillance, Epidemiology, and End Results Analysis from 1998 to 2014. 
  • Decreasing rates of axillary lymph node dissections over time: Implications for surgical resident exposure and operative skills development. 
  • Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. 
  • Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ. 
  • Deep learning for identifying radiogenomic associations in breast cancer. 
  • Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study. 
  • Defining Mastectomy Skin Flap Necrosis: A Systematic Review of the Literature and a Call for Standardization. 
  • Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. 
  • Definition of a functional single nucleotide polymorphism in the cell migration inhibitory gene MIIP that affects the risk of breast cancer. 
  • Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. 
  • Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. 
  • Delay of transverse rectus abdominis myocutaneous flap reconstruction improves flap reliability in the obese patient. 
  • Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. 
  • Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States. 
  • Deletions and point mutations of p16,p15 gene in primary tumors and tumor cell lines. 
  • Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. 
  • Delivery rate affects uptake of a fluorescent glucose analog in murine metastatic breast cancer. 
  • Delivery-corrected imaging of fluorescently-labeled glucose reveals distinct metabolic phenotypes in murine breast cancer. 
  • Delphi survey of intercontinental experts to identify areas of consensus on the use of indocyanine green angiography for tissue perfusion assessment during plastic and reconstructive surgery. 
  • Demand for Cancer Screening Services: Results From Randomized Controlled Discrete Choice Experiments. 
  • Demographics (1950-1987) of breast cancer in birth cohorts of older women. 
  • Depression and Anxiety Disorders among Hospitalized Women with Breast Cancer. 
  • Depression is associated with worse outcomes among women undergoing breast reconstruction following mastectomy. 
  • Deriving clinically meaningful cut-scores for fatigue in a cohort of breast cancer survivors: a Health, Eating, Activity, and Lifestyle (HEAL) Study. 
  • Design of FRESH START: a randomized trial of exercise and diet among cancer survivors. 
  • Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer. 
  • Detailed methods of two home-based vegetable gardening intervention trials to improve diet, physical activity, and quality of life in two different populations of cancer survivors. 
  • Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool. 
  • Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. 
  • Detection of metastatic disease from carcinoma of the breast: limited value of full lung tomography. 
  • Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Determination of hormonal steroid concentrations in biological extracts by high resolution mass fragmentography. 
  • Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. 
  • Developing a claim-based version of the ACE-27 comorbidity index: a comparison with medical record review. 
  • Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. 
  • Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. 
  • Development and application of a suite of 4-D virtual breast phantoms for optimization and evaluation of breast imaging systems. 
  • Development and external validation of a breast cancer absolute risk prediction model in Chinese population. 
  • Development and pilot testing of an mHealth behavioral cancer pain protocol for medically underserved communities. 
  • Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery. 
  • Development of a breast cancer screening & research program. 
  • Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans. 
  • Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. 
  • Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. 
  • Diagnosis of breast cancer using diffuse reflectance spectroscopy: Comparison of a Monte Carlo versus partial least squares analysis based feature extraction technique. 
  • Diagnosis of breast cancer using fluorescence and diffuse reflectance spectroscopy: a Monte-Carlo-model-based approach. 
  • Diagnosis of posttransplant granulocytic sarcoma by fine-needle aspiration cytology and flow cytometry. 
  • Diagnostic Performance of an Artificial Intelligence System in Breast Ultrasound. 
  • Diagnostic Value of Ultrasound in Female Patients With Nipple Discharge. 
  • Diagnostic Versus Screening Mammography Recommendations for Postlumpectomy Imaging Surveillance of Patients With Breast Cancer. 
  • Diagnostic performance characteristics of architectural features revealed by high spatial-resolution MR imaging of the breast. 
  • Diagnostic thoracic-computed tomography in radiotherapy for loco-regional recurrent breast carcinoma. 
  • Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. 
  • Dideoxy fingerprinting assay for BRCA1 mutation analysis. 
  • Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors. 
  • Dietary omega-3 fatty acid intake impacts peripheral blood DNA methylation -anti-inflammatory effects and individual variability in a pilot study. 
  • Dietary patterns differ between urban and rural older, long-term survivors of breast, prostate, and colorectal cancer and are associated with body mass index. 
  • Differences between computer-aided diagnosis of breast masses and that of calcifications. 
  • Differences in baseline characteristics and outcomes at 1- and 2-year follow-up of cancer survivors accrued via self-referral versus cancer registry in the FRESH START Diet and exercise trial. 
  • Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. 
  • Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. 
  • Differences in urinary incontinence between Hispanic and non-Hispanic white women: a population-based study. 
  • Different patterns of angiogenesis in sarcomas and carcinomas. 
  • Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer. 
  • Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. 
  • Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. 
  • Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. 
  • Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress. 
  • Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. 
  • Differential psychological effects of cognitive-behavioral stress management among breast cancer patients with high and low initial cancer-specific distress. 
  • Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. 
  • Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. 
  • Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. 
  • Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers. 
  • Digital mammography image quality: image display. 
  • Digital mammography: comparative performance of color LCD and monochrome CRT displays. 
  • Digital mammography: effects of reduced radiation dose on diagnostic performance. 
  • Direct Optical Imaging of Graphene In Vitro by Nonlinear Femtosecond Laser Spectral Reshaping 
  • Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. 
  • Direct-to-Implant Breast Reconstruction in Women Older than 65 Years: A Retrospective Analysis of Complication Rate and Overall Outcomes. 
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. 
  • Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. 
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 
  • Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements. 
  • Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer. 
  • Discussing Health Care Expenses in the Oncology Clinic: Analysis of Cost Conversations in Outpatient Encounters. 
  • Discussion of "Combining biomarkers to optimize patient treatment recommendation". 
  • Disease characteristics and mortality among Asian women with breast cancer. 
  • Disparities Associated With Patient Adherence of Post-Breast-Conserving Surgery Surveillance Imaging Protocols. 
  • Disparities Associated With Patient Adherence to BI-RADS 3 Assessment Follow-up Recommendations for Mammography and Ultrasound. 
  • Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women With Breast Cancer. 
  • Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. 
  • Disparities in breast carcinoma treatment in Asian/Pacific Islander women. A challenge to the provider. 
  • Disparities in cancer funding. 
  • Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. 
  • Disparities in the uptake of digital breast tomosynthesis for breast cancer screening: A retrospective cohort study. 
  • Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study. 
  • Disparity mapping applied to sonography of the breast: technical note. 
  • Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study. 
  • Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. 
  • Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. 
  • Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. 
  • Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. 
  • Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected? 
  • Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity? 
  • Do serum biomarkers really measure breast cancer? 
  • Does Angiosarcoma of the Breast Need Nodal Staging? 
  • Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy? 
  • Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy? 
  • Does Breast Imaging Experience During Residency Translate Into Improved Initial Performance in Digital Breast Tomosynthesis? 
  • Does Localization Technique Matter for Non-palpable Breast Cancers? 
  • Does Surgeon Training Affect Patient Perception of Surgeon Skill in DIEP Flap Breast Reconstruction? 
  • Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. 
  • Does practice make perfect? Resident experience with breast surgery influences excision adequacy. 
  • Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis. 
  • Does the Broaden-and-Build Theory Explain Reduction in Social Disruption After a Brief Relaxation Intervention for Women With Breast Cancer Undergoing Treatment? 
  • Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance? 
  • Does the preparation and utilization of 99mTc-sulfur colloid affect the outcomes of breast lymphoscintigraphy? 
  • Does the proven benefit of mammography extend to breast cancer patients over age 70? 
  • Does time to definitive treatment matter in patients with ductal carcinoma in situ? 
  • Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. 
  • Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. 
  • Dose dependence of mass and microcalcification detection in digital mammography: free response human observer studies. 
  • Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Dosimetric comparison of 3D conformal, IMRT, and V-MAT techniques for accelerated partial-breast irradiation (APBI). 
  • Dosimetric comparison of preoperative single-fraction partial breast radiotherapy techniques: 3D CRT, noncoplanar IMRT, coplanar IMRT, and VMAT. 
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer. 
  • Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. 
  • Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. 
  • Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. 
  • Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. 
  • Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. 
  • Dreams prior to biopsy for suspected breast cancer: A preliminary survey. 
  • Dual-emissive, oxygen-sensing boron nanoparticles quantify oxygen consumption rate in breast cancer cells. 
  • Dual-energy contrast-enhanced breast tomosynthesis: optimization of beam quality for dose and image quality. 
  • Ductal Carcinoma In Situ Biology, Language, and Active Surveillance: A Survey of Breast Radiologists' Knowledge and Opinions. 
  • Ductal Carcinoma In Situ in Pregnant Women. 
  • Ductal Carcinoma in Situ: State-of-the-Art Review. 
  • Ductal carcinoma in situ (DCIS): posttreatment follow-up care among Latina and non-Latina White women. 
  • Ductal carcinoma in situ in BRCA mutation carriers. 
  • Ductal carcinoma in situ: a review of recent advances. 
  • Ductal carcinoma in situ: atypical mammographic appearances. 
  • Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women. 
  • Ductal carcinoma in situ: to treat or not to treat, that is the question. 
  • Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. 
  • Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. 
  • Duration of Trastuzumab. In matters of the heart, one size may not fit all? 
  • Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. 
  • EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. 
  • ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. 
  • Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center. 
  • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response? 
  • Early life growth, socioeconomic status, and mammographic breast density in an urban US birth cohort. 
  • Early supportive medication use and end-of-life care among Medicare beneficiaries with advanced breast cancer. 
  • Early-stage Breast Cancer: Tailored External Beam Fractionation Approaches for Treatment of the Whole or Partial Breast. 
  • Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. 
  • Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. 
  • Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. 
  • Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. 
  • Economic implications of 21-gene recurrence score assay: US multicenter experience. 
  • Economic outcomes of breast cancer survivorship: CALGB study 79804. 
  • Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. 
  • Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. 
  • Editorial for "Harmonization of Quantitative Parenchymal Enhancement in T1-Weighted Breast MRI". 
  • Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. 
  • Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. 
  • Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. 
  • Effect of Regional Hospital Market Competition on Use Patterns of Free Flap Breast Reconstruction. 
  • Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. 
  • Effect of case selection on the performance of computer-aided detection schemes. 
  • Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. 
  • Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. 
  • Effect of human variability on independent double reading in screening mammography. 
  • Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial. 
  • Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. 
  • Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. 
  • Effect of patient history data on the prediction of breast cancer from mammographic findings with artificial neural networks. 
  • Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. 
  • Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. 
  • Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 
  • Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. 
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. 
  • Effect of virtual reality on time perception in patients receiving chemotherapy. 
  • Effect of vitamin E on tamoxifen-treated breast cancer cells. 
  • Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹ At-Labeled Anti-HER2 Single-Domain Antibody Fragment. 
  • Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. 
  • Effective patient-provider communication about sexual concerns in breast cancer: a qualitative study. 
  • Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid. 
  • Effectiveness of telephone counseling for mammography: results from five randomized trials. 
  • Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial. 
  • Effects of a mammography decision-making intervention at 12 and 24 months. 
  • Effects of advanced nursing care on quality of life and cost outcomes of women diagnosed with breast cancer. 
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
  • Effects of diet and exercise on weight-related outcomes for breast cancer survivors and their adult daughters: an analysis of the DAMES trial. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. 
  • Effects of long-term estrogen replacement therapy. II. Neoplasia. 
  • Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. 
  • Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery. 
  • Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. 
  • Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Efficacy of a multimedia intervention in facilitating breast cancer patients' clinical communication about sexual health: Results of a randomized controlled trial. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. 
  • Electronic patient-reported data capture as a foundation of rapid learning cancer care. 
  • Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. 
  • Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer. 
  • Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. 
  • Eligible and not eligible studies in the recent meta-analysis about p53 polymorphism and breast cancer risk. 
  • Embracing the complexity of genomic data for personalized medicine. 
  • Emotional arousal predicts observed social support in German and American couples talking about breast cancer. 
  • Emotions and social relationships for breast and gynecologic patients: a qualitative study of coping with recurrence. 
  • Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance. 
  • Endobronchial metastatic breast cancer with pagetoid histology mimicking bronchial pagetoid squamous cell carcinoma in situ. 
  • Endocrine therapy in early-stage breast cancer care: defining the appropriate regimen and time frame. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. 
  • Endoscopic axillary exploration and sentinel lymphadenectomy. 
  • Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. 
  • Environmental Quality and Invasive Breast Cancer. 
  • Environmental contaminants and body fat distribution. 
  • Environmental factors in relation to breast cancer characterized by p53 protein expression. 
  • Eosinophilia in cancer and its regulation by sex hormones. 
  • EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
  • Epidemiology of basal-like breast cancer. 
  • Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. 
  • Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. 
  • Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. 
  • Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. 
  • Epirubicin and ifosfamide in metastatic breast cancer. 
  • Epirubicin: is it like doxorubicin in breast cancer? A clinical review. 
  • Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. 
  • Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. 
  • Era of Individualization of the Surgical Treatment of Breast Cancer: Similar Problems Can Sometimes Be Treated Differently. 
  • Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. 
  • Erythropoietin Stimulates Tumor Growth via EphB4. 
  • Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. 
  • Estimate of breast cancer risk reduction with weight loss. 
  • Estimating Tumor Growth Rates In Vivo. 
  • Estimating crude or common odds ratios in case-control studies with informatively missing exposure data. 
  • Estimating measures of diagnostic accuracy when some covariate information is missing. 
  • Estimating net benefits and harms of screening mammography in women age 40 to 49 years. 
  • Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. 
  • Estimating the frequency of indolent breast cancer in screening trials. 
  • Estimating the magnitude of clinical benefit of local therapy in patients with DCIS. 
  • Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. 
  • Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. 
  • Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. 
  • Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. 
  • Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response. 
  • Estrogen receptor determination in percutaneous bone marrow biopsies of patients with metastatic breast cancer. 
  • Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. 
  • Estrogen, estrogen plus progestin therapy, and risk of breast cancer. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. 
  • Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. 
  • Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. 
  • Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. 
  • Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. 
  • Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. 
  • Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergism. 
  • Ethical ramifications of alternative means of recruiting research participants from cancer registries. 
  • Evaluating a couple-based intervention addressing sexual concerns for breast cancer survivors: study protocol for a randomized controlled trial. 
  • Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. 
  • Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. 
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. 
  • Evaluating the effect of image preprocessing on an information-theoretic CAD system in mammography. 
  • Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy. 
  • Evaluating the relationship between ductal carcinoma in situ, calcifications, and margin status in patients undergoing breast conserving surgery. 
  • Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses. 
  • Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial. 
  • Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. 
  • Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. 
  • Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? 
  • Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. 
  • Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. 
  • Evaluation of a recombinant yeast cell estrogen screening assay. 
  • Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. 
  • Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers. 
  • Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. 
  • Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. 
  • Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo. 
  • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. 
  • Evaluation of expression based markers for the detection of breast cancer cells. 
  • Evaluation of fully 3-D emission mammotomography with a compact cadmium zinc telluride detector. 
  • Evaluation of information-theoretic similarity measures for content-based retrieval and detection of masses in mammograms. 
  • Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. 
  • Evaluation of the Axillary Surgery Performed in Clinically Node-Positive Breast Cancer Patients Following Neoadjuvant Chemotherapy. 
  • Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. 
  • Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. 
  • Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. 
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. 
  • Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. 
  • Examining accuracy of screening mammography using an event order model. 
  • Examining health-related quality of life patterns in women with breast cancer. 
  • Examining potential gaps in supportive medication use for US and foreign-born Hispanic women with breast cancer. 
  • Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. 
  • Exercise among breast and prostate cancer survivors--what are their barriers? 
  • Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804. 
  • Exercise behavior and patient-reported outcomes in women with early breast cancer receiving locoregional radiation therapy. 
  • Exercise training partially rescues impaired mucosal associated invariant t-cell mobilization in breast cancer survivors compared to healthy older women. 
  • Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. 
  • Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. 
  • Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). 
  • Experience with reduction mammaplasty combined with breast conservation therapy in the treatment of breast cancer. 
  • Experimental spectral measurements of heavy K-edge filtered beams for x-ray computed mammotomography. 
  • Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. 
  • Exploration of Exercise Outcome Expectations Among Breast Cancer Survivors. 
  • Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. 
  • Exploring the potential of context-sensitive CADe in screening mammography. 
  • Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. 
  • Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. 
  • Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. 
  • Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. 
  • Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. 
  • Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. 
  • Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. 
  • Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. 
  • Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. 
  • Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 
  • Extant health behaviors and uptake of standardized vs tailored health messages among cancer survivors enrolled in the FRESH START trial: a comparison of fighting-spirits vs fatalists. 
  • Extended field-of-view two-dimensional ultrasonography of the breast: improvement in lesion documentation. 
  • Extramedullary hematopoiesis during therapy with granulocyte colony-stimulating factor. 
  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. 
  • FAK overexpression and p53 mutations are highly correlated in human breast cancer. 
  • FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. 
  • FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. 
  • FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. 
  • FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. 
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. 
  • Facilitated cascade testing (FaCT): a randomized controlled trial. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Factors Affecting Time to Surgery in Breast Cancer Patients. 
  • Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors. 
  • Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). 
  • Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. 
  • Factors affecting outcome in locally advanced breast cancer. 
  • Factors associated with annual-interval mammography for women in their 40s. 
  • Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic. 
  • Factors associated with perceived risk of breast cancer among women attending a screening program. 
  • Factors associated with repeat mammography screening. 
  • Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience. 
  • Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. 
  • False Information About Breast Cancer Screening. 
  • Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. 
  • Family history of gynaecological cancers: relationships to the incidence of breast cancer prior to age 55. 
  • Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. 
  • Fat Grafting and the Palpable Breast Mass in Implant-Based Breast Reconstruction: Incidence and Implications. 
  • Fat Grafting-More Than Just the Hype. 
  • Fat necrosis in the breast: sonographic features. 
  • Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous stem cell transplant. 
  • Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. 
  • Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. 
  • Fatty acid metabolites in rapidly proliferating breast cancer. 
  • Feasibility of a mindful yoga program for women with metastatic breast cancer: results of a randomized pilot study. 
  • Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence. 
  • Feasibility of using technology to disseminate evidence to rural nurses and improve patient outcomes. 
  • Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. 
  • Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. 
  • Features of benign granular cell tumor on fine needle aspiration. 
  • Features of occult invasion in biopsy-proven DCIS at breast MRI. 
  • Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. 
  • Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. 
  • Fertility drugs and the risk of breast cancer: a meta-analysis and review. 
  • Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. 
  • Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer-reply. 
  • Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment. 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Final results of the Department of Defense multicenter breast lymphatic mapping trial. 
  • Financial Costs and Burden Related to Decisions for Breast Cancer Surgery. 
  • Finding the minimal intervention needed for sustained mammography adherence. 
  • Findings on Surveillance Imaging After Preoperative Partial Breast Irradiation for Early Stage Breast Cancer. 
  • Fine-needle aspiration of inflammatory carcinoma of the breast. 
  • First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. 
  • Flow cytometric DNA analysis of excised breast lesions: use of fresh tissue needle aspirates obtained under guidance with mammography of the specimen. 
  • Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer. 
  • Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. 
  • Fluctuating response of a cystic vestibular schwannoma to radiosurgery: case report. 
  • Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. 
  • Fluorouracil and leucovorin in advanced breast cancer. 
  • Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma. 
  • Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. 
  • Focal Breast Pain: Does Breast Density Affect the Need for Ultrasound? 
  • Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. Letter. 
  • Focal fibrosis: a common breast lesion diagnosed at imaging-guided core biopsy. 
  • Forecasting health: data needs and implications for model structure. 
  • Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. 
  • Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. 
  • Foxo-dependent Par-4 Upregulation Prevents Long-term Survival of Residual Cells Following PI3K-Akt Inhibition. 
  • Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. 
  • Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. 
  • Frailty and health-related quality of life in older women with breast cancer. 
  • Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). 
  • Frequency of Breast Cancer Thoughts and Lifetime Risk Estimates: A Multi-Institutional Survey of Women Undergoing Screening Mammography. 
  • Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI. 
  • Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. 
  • Frequency of breast cancer subtypes among African American women in the AMBER consortium. 
  • From breast to the brain: unraveling the puzzle of metastasis organotropism. 
  • Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases. 
  • Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. 
  • Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. 
  • Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. 
  • Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. 
  • Functional assessment and the cancer survivor: something old, something new. 
  • Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. 
  • Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. 
  • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. 
  • Functional significance of erythropoietin receptor expression in breast cancer. 
  • Functional status declines among cancer survivors: trajectory and contributing factors. 
  • Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. 
  • G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis. 
  • G12 signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. 
  • Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. 
  • Galpha12 and Galpha13 negatively regulate the adhesive functions of cadherin. 
  • Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. 
  • Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gemcitabine in the management of metastatic breast cancer: a systematic review. 
  • Gene expression predictors of breast cancer outcomes. 
  • Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. 
  • Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. 
  • Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. 
  • Gene expression profiling for prediction of clinical characteristics of breast cancer. 
  • Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. 
  • Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers. 
  • Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. 
  • Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. 
  • Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. 
  • General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study. 
  • General performance on a numeracy scale among highly educated samples. 
  • Generalized cutaneous metastases from breast adenocarcinoma. 
  • Generation of a polyclonal fab phage display library to the human breast carcinoma cell line BT-20. 
  • Generation of reactive oxygen species by xanthine derivatives in MDA-MB-231 human breast cancer cells. 
  • Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. 
  • Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations. 
  • Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. 
  • Genetic basis for p53 overexpression in human breast cancer. 
  • Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? 
  • Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. 
  • Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. 
  • Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. 
  • Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years. 
  • Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. 
  • Genetic variants improve breast cancer risk prediction on mammograms. 
  • Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged  
  • Genetic variants of genes in the NER pathway associated with risk of breast cancer: A large-scale analysis of 14 published GWAS datasets in the DRIVE study. 
  • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. 
  • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genetics of Breast Cancer: Risk Models, Who to Test, and Management Options. 
  • Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. 
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 
  • Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. 
  • Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. 
  • Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ. 
  • Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. 
  • Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. 
  • Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. 
  • Genomic landscapes of breast fibroepithelial tumors. 
  • Genomic prediction of locoregional recurrence after mastectomy in breast cancer. 
  • Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival. 
  • Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing. 
  • Germline Genetic Testing: What the Breast Surgeon Needs to Know. 
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. 
  • Global analysis of protein folding thermodynamics for disease state characterization. 
  • Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. 
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. 
  • Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. 
  • Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. 
  • Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. 
  • Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: convergence and divergence of the two recent meta-analyses. 
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. 
  • Goal-Driven Beam Setting Optimization for Whole-Breast Radiation Therapy. 
  • Gold nanoshell bioconjugates for molecular imaging in living cells. 
  • Gold nanostars: surfactant-free synthesis, 3D modelling, and two-photon photoluminescence imaging. 
  • Granular cell tumors of the breast. Steroid receptor analysis and localization of carcinoembryonic antigen, myoglobin, and S100 protein. 
  • Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 
  • Greater mindfulness associated with lower pain, fatigue, and psychological distress in women with metastatic breast cancer. 
  • Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions. 
  • Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. 
  • Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. 
  • HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. 
  • HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 
  • HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. 
  • HER2 dendritic cell vaccines. 
  • HER2-positive breast cancer brain metastasis: A new and exciting landscape. 
  • HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. 
  • HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. 
  • HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. 
  • Hair regrowth after cancer therapy. 
  • Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration. 
  • Harvest for Health, a Randomized Controlled Trial Testing a Home-Based, Vegetable Gardening Intervention Among Older Cancer Survivors Across Alabama: An Analysis of Accrual and Modifications Made in Intervention Delivery and Assessment During COVID-19. 
  • Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. 
  • Health care utilization, lifestyle, and emotional factors and mammography practices in the Childhood Cancer Survivor Study. 
  • Health promotion interventions for disadvantaged women: overview of the WISEWOMAN projects. 
  • Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. 
  • Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. 
  • Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. 
  • Healthcare access and mammography screening in Michigan: a multilevel cross-sectional study. 
  • Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades. 
  • Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages. 
  • Helical CT for detecting focal liver lesions in patients with breast carcinoma: comparison of noncontrast phase, hepatic arterial phase, and portal venous phase. 
  • Helical tomotherapy for bilateral breast cancer: Clinical experience. 
  • Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • Hemolytic anemia and metastatic carcinoma: case report and literature review. 
  • Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. 
  • Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15). 
  • Hepatic parenchymal enhancement during triple-phase helical CT: can it be used to predict which patients with breast cancer will develop hepatic metastases? 
  • Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. 
  • Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. 
  • Heterogeneity and vascular permeability of breast cancer brain metastases. 
  • Hierarchical Convolutional Neural Networks for Segmentation of Breast Tumors in MRI With Application to Radiogenomics. 
  • High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. 
  • High frequency of aberrant p16(INK4A) expression in human breast cancer. 
  • High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. 
  • High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. 
  • High-dimensional variable selection in meta-analysis for censored data. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. 
  • High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. 
  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. 
  • High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. 
  • High-resolution MR imaging of the breast: clinical context. 
  • Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. 
  • Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. 
  • Highlights of the 2008 San Antonio Breast Cancer Symposium. 
  • Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. 
  • Histological assessment of breast lesions identified exclusively by magnetic resonance. 
  • Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. 
  • Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. 
  • Hodgkin's lymphoma of the breast. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • Hope and social support utilisation among different age groups of women with breast cancer and their spouses. 
  • Hormonal and personal effects on estrogen receptors in breast cancer. 
  • Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. 
  • Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. 
  • Hospital visitors as controls. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • How Informed Is the Decision About Breast Reconstruction After Mastectomy?: A Prospective, Cross-sectional Study. 
  • How Low Can We Go-and Should We? Risk Reduction for Minimal-Volume DCIS. 
  • How can we optimize treatment of HER2-positive metastatic breast cancer? 
  • How changes in physical activity relate to fatigue interference, mood, and quality of life during treatment for non-metastatic breast cancer. 
  • How experience and training influence mammography expertise. 
  • How making a risk estimate can change the feel of that risk: shifting attitudes toward breast cancer risk in a general public survey. 
  • How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. 
  • How stereotactic core-needle biopsy affected breast fine-needle aspiration utilization: an 11-year institutional review. 
  • Hsp90, an unlikely ally in the war on cancer. 
  • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. 
  • Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. 
  • Human breast cancer specimens: diffraction-enhanced imaging with histologic correlation--improved conspicuity of lesion detail compared with digital radiography. 
  • Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. 
  • Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. 
  • Hyperlucent lung after radiation therapy. 
  • Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. 
  • Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. 
  • Hypertensive reactions associated with paclitaxel. 
  • Hyperthermia MRI temperature measurement: evaluation of measurement stabilisation strategies for extremity and breast tumours. 
  • Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data. 
  • Hyperthermia for locally advanced breast cancer. 
  • Hysterectomy, tubal sterilization, and the risk of breast cancer. 
  • IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition. 
  • ISG15 as a novel tumor biomarker for drug sensitivity. 
  • Iatrogenic lesions of soft tissue and bone. 
  • Identification and characterization of K12 (SECTM1), a novel human gene that encodes a Golgi-associated protein with transmembrane and secreted isoforms. 
  • Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. 
  • Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. 
  • Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer. 
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. 
  • Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. 
  • Identification of novel epithelial ovarian cancer loci in women of African ancestry. 
  • Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. 
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. 
  • Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. 
  • Identification of the breast cancer susceptibility gene BRCA2. 
  • Identification of tumor angiogenesis-related genes by subtractive hybridization. 
  • Identification of women at increased risk for breast cancer in a population-based screening program. 
  • Identifying error-making patterns in assessment of mammographic BI-RADS descriptors among radiology residents using statistical pattern recognition. 
  • Images in clinical medicine. Rapid progression of basal-type breast cancer. 
  • Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ. 
  • Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. 
  • Imaging of late complications from mantle field radiation in lymphoma patients. 
  • Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. 
  • Imaging-Guided Core-Needle Breast Biopsy: Impact of Meditation and Music Interventions on Patient Anxiety, Pain, and Fatigue. 
  • Imaging-guided core biopsies in the breast. 
  • Imaging-guided core needle biopsy of papillary lesions of the breast. 
  • Immediate Breast Reconstruction Allows for the Timely Initiation of Postmastectomy Radiation Therapy. 
  • Immediate reconstruction of the breast following modified radical mastectomy for carcinoma of the breast. 
  • Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. 
  • Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). 
  • Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? 
  • Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. 
  • Immunofluorescent localization of a novel progesterone receptor(s) in a T47D-Y breast cancer cell line lacking genomic progesterone receptor expression. 
  • Immunoglobulin localization in benign and malignant lesions of the human mammary gland. 
  • Immunological approach to the study of hormone action: regulation of the phosphorylation state of protein phosphatase inhibitor-1 by hormones. 
  • Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. 
  • Immunonanoshells for targeted photothermal ablation of tumor cells. 
  • Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. 
  • Immunoreaction at 43 kDa with anti-ubiquitin antibody in breast neoplasms. 
  • Immunotargeted nanoshells for integrated cancer imaging and therapy. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. 
  • Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. 
  • Impact of Breast Density Notification Legislation on Radiologists' Practices of Reporting Breast Density: A Multi-State Study. 
  • Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. 
  • Impact of Improved Screening Mammography Recall Lay Letter Readability on Patient Follow-Up. 
  • Impact of National Cancer Institute revised mammography screening guidelines on women 40-49. 
  • Impact of Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers 
  • Impact of Postoperative Antibiotic Prophylaxis Duration on Surgical Site Infections in Autologous Breast Reconstruction. 
  • Impact of Telephone Communication on Patient Adherence With Follow-Up Recommendations After an Abnormal Screening Mammogram. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. 
  • Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. 
  • Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. 
  • Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function. 
  • Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. 
  • Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. 
  • Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer. 
  • Impact of ductal carcinoma in situ terminology on patient treatment preferences. 
  • Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. 
  • Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. 
  • Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. 
  • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. 
  • Impact of mailed and automated telephone reminders on receipt of repeat mammograms: a randomized controlled trial. 
  • Impact of maternal breast cancer on school-aged children in Saudi Arabia. 
  • Impact of missing data in evaluating artificial neural networks trained on complete data. 
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. 
  • Impact of patient-specific factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer. 
  • Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes. 
  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. 
  • Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis. 
  • Impact of the COVID-19 Pandemic on Breast Cancer Screening and Operative Treatment. 
  • Impact of the COVID-19 Pandemic on Breast Imaging: An Analysis of the National Mammography Database. 
  • Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. 
  • Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. 
  • Impact of volumetric modulated arc therapy technique on treatment with partial breast irradiation. 
  • Implementation of Abbreviated Breast MRI for Screening: AJR Expert Panel Narrative Review. 
  • Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. 
  • Implementing stereotactic accelerated partial breast irradiation using magnetic resonance guided radiation therapy. 
  • Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. 
  • Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer. 
  • Implications of missing data on reported breast cancer mortality. 
  • Importance of point-by-point back projection correction for isocentric motion in digital breast tomosynthesis: relevance to morphology of structures such as microcalcifications. 
  • Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians. 
  • Importance of race on breast cancer survival. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. 
  • Improving Patient Comprehension of Screening Mammography Recall Lay Letters. 
  • Improving State-Mandated Breast Density Notifications. 
  • Improving breast cancer risk prediction by using demographic risk factors, abnormality features on mammograms and genetic variants. 
  • Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. 
  • Improving health engagement and lifestyle management for breast cancer survivors with diabetes. 
  • Improving mammographic decision accuracy by incorporating observer ratings with interpretation time. 
  • Improving understanding of adjuvant therapy options by using simpler risk graphics. 
  • Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial. 
  • In Estimating Overdiagnosis, Details Matter. 
  • In Situ Drug Delivery to Breast Cancer-Associated Extracellular Matrix. 
  • In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer. 
  • In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. 
  • In defense of screening for breast cancer with magnetic resonance imaging--reply. 
  • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 
  • In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. 
  • In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. 
  • In vivo measurements of ultrasonic beam distortion in the breast. 
  • In vivo particle tracking and photothermal ablation using plasmon-resonant gold nanostars. 
  • Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). 
  • Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014. 
  • Incidence of autoimmune disease in patients after breast reconstruction with silicone gel implants versus autogenous tissue: a preliminary report. 
  • Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. 
  • Incidence rate of breast cancer in young women. 
  • Incidence rate of breast cancer in young women. 
  • Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. 
  • Incidental minimal atypical lobular hyperplasia on core needle biopsy: correlation with findings on follow-up excision. 
  • Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. 
  • Incorporation of a Laguerre-Gauss channelized Hotelling observer for false-positive reduction in a mammographic mass CAD system. 
  • Increased Fiber Intake Decreases Premenopausal Breast Cancer Risk. 
  • Increased Use of Porch or Backyard Nature during COVID-19 Associated with Lower Stress and Better Symptom Experience among Breast Cancer Patients. 
  • Increased erbB-2 gene copies and expression in multiple stages of breast cancer. 
  • Increased sectioning of pathologic specimens with ductal carcinoma in situ of the breast: are there clinical consequences? 
  • Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. 
  • Increasing compliance with mammography recommendations: health assessment forms. 
  • Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan. 
  • Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Individual responses to chemotherapy-induced oxidative stress. 
  • Individual, Area, and Provider Characteristics Associated With Care Received for Stages I to III Breast Cancer in a Multistate Region of Appalachia. 
  • Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations. 
  • Indocyanine green-loaded nanoparticles for image-guided tumor surgery. 
  • Infectious complications following breast reconstruction with expanders and implants. 
  • Inference for case-control studies when exposure status is both informatively missing and misclassified. 
  • Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. 
  • Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study. 
  • Inflammatory breast carcinoma. Effective multimodal approach. 
  • Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. 
  • Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ. 
  • Information-theoretic CAD system in mammography: entropy-based indexing for computational efficiency and robust performance. 
  • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. 
  • Informing women about their breast cancer risks: truth and consequences. 
  • Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. 
  • Inherently stealthy and highly tumor-selective gold nanoraspberries for photothermal cancer therapy. 
  • Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. 
  • Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation. 
  • Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. 
  • Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. 
  • Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. 
  • Initial Clinical Experience with Stationary Digital Breast Tomosynthesis. 
  • Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. 
  • Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. 
  • Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells. 
  • Insurance-Based Differences in Time to Diagnostic Follow-up after Positive Screening Mammography. 
  • Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. 
  • Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. 
  • Integrated genomic characterization of endometrial carcinoma. 
  • Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. 
  • Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. 
  • Integrating machine learning and physician knowledge to improve the accuracy of breast biopsy. 
  • Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. 
  • Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. 
  • Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. 
  • Integrative genomic approaches identify IKBKE as a breast cancer oncogene. 
  • Integrative tumor board: recurrent breast cancer or new primary? UCSF Osher Center for Integrative Medicine and UCSF Carol Franc Buck Breast Care Center. 
  • Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. 
  • Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. 
  • Interest in BRCA1/2 testing in a primary care population. 
  • Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells. 
  • Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. 
  • Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. 
  • Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. 
  • Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. 
  • Interobserver Variability Between Breast Imagers Using the Fifth Edition of the BI-RADS MRI Lexicon. 
  • Interobserver variability in identification of breast tumors in MRI and its implications for prognostic biomarkers and radiogenomics. 
  • Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intrabreath analysis of carbon monoxide uptake during exercise in patients at risk for lung injury. 
  • Intracellular measurements in mammary carcinoma cells using fiber-optic nanosensors. 
  • Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. 
  • Intraductal Papilloma on Breast Biopsy: Upstaging Rate and Implications for Practice Guidelines. 
  • Intraductal Papilloma with Benign Pathology on Breast Core Biopsy: To Excise or Not? 
  • Intramammary lymph nodes: cytologic findings and implications for fine-needle aspiration cytology diagnosis of breast nodules. 
  • Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. 
  • Intraoperative radiation therapy. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. 
  • Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. 
  • Intratumoral heterogeneity in primary breast carcinoma: study of concurrent parameters. 
  • Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. 
  • Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Invasive breast cancer. 
  • Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer. 
  • Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia. 
  • Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. 
  • Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer. 
  • Involvement of the mt1 melatonin receptor in human breast cancer. 
  • Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures. 
  • Is Bigger Better?: The Effect of Hospital Consolidation on Index Hospitalization Costs and Outcomes Among Privately Insured Recipients of Immediate Breast Reconstruction. 
  • Is Excisional Biopsy Needed for Pure FEA Diagnosed on a Core Biopsy? 
  • Is Excisional Biopsy and Chemoprevention Warranted in Patients With Atypical Lobular Hyperplasia on Core Biopsy? 
  • Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy? 
  • Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? 
  • Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? 
  • Is radial scar on core needle biopsy a risk factor for malignancy? A single-center retrospective review and implications for management. 
  • Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? 
  • Is surgical excision of core biopsy proven benign papillomas of the breast necessary? 
  • Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance? 
  • Is there an increased risk of local recurrence under the heart block in patients with left-sided breast cancer? 
  • Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. 
  • Isolated liver metastasis from a malignant phyllodes presenting with hemoperitoneum. 
  • Isolated tumor cells in breast cancer. 
  • Isolation and initial characterization of the BRCA2 promoter. 
  • Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal. 
  • It's the amount of thought that counts: when ambivalence contributes to mammography screening delay. 
  • JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. 
  • Job loss, return to work, and multidimensional well-being after breast cancer treatment in working-age Black and White women. 
  • Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. 
  • Joint model for a diagnostic test without a gold standard in the presence of a dependent terminal event. 
  • Joint modeling of sensitivity and specificity. 
  • Journey toward computer-aided diagnosis: role of image texture analysis. 
  • Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Knowledge about genomic recurrence risk testing among breast cancer survivors. 
  • Knowledge discovery from structured mammography reports using inductive logic programming. 
  • LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. 
  • LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. 
  • Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. 
  • Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 
  • Lactation and breast cancer risk. 
  • Language barriers and patient-centered breast cancer care. 
  • Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. 
  • Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. 
  • Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 
  • Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using Limited Proteolysis. 
  • Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using SILAC-SPROX. 
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. 
  • Laser scanning cytometry quantification of estrogen receptors in breast cancer. 
  • Latent class model characterization of neighborhood socioeconomic status. 
  • Latent factor analysis to discover pathway-associated putative segmental aneuploidies in human cancers. 
  • Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors. 
  • Learning to distinguish progressive and non-progressive ductal carcinoma in situ. 
  • Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low? 
  • Leptomeningeal failure in patients with breast cancer receiving stereotactic radiosurgery for brain metastases. 
  • Letrozole in the treatment of breast cancer. 
  • Letter to the Editor - "Is it ethical to incentivize mammography screening in Medicaid populations? - A policy review and conceptual analysis". 
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
  • Leukocyte composition of human breast cancer. 
  • Leukocyte telomere length, breast cancer risk in the offspring: the relations with father's age at birth. 
  • Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. 
  • Life expectancy benefits of cancer screening in the end-stage renal disease population. 
  • Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO's Study on Global Ageing and Adult Health (SAGE). 
  • Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. 
  • Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. 
  • Light scattering measurements of subcellular structure provide noninvasive early detection of chemotherapy-induced apoptosis. 
  • Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel. 
  • Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. 
  • Limited family structure and breast cancer risk. 
  • Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. 
  • Liver metastases from breast cancer: long-term survival after curative resection. 
  • LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. 
  • Lobular breast cancer series: imaging. 
  • Lobular carcinoma in situ: observation without surgery as an appropriate therapy. 
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. 
  • Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. 
  • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). 
  • Localization of I-131-labeled goat and primate anti-carcinoembryonic antigen(CEA) antibodies in patients with cancer. 
  • Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1. 
  • Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy. 
  • Logical Differential Prediction Bayes Net, improving breast cancer diagnosis for older women. 
  • Loneliness and mental health during the COVID-19 pandemic in older breast cancer survivors and noncancer controls. 
  • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. 
  • Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. 
  • Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. 
  • Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term clinical outcome of immediate reconstruction after mastectomy. 
  • Long-term dietary outcomes of the FRESH START intervention for breast and prostate cancer survivors. 
  • Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. 
  • Long-term outcomes of the FRESH START trial: exploring the role of self-efficacy in cancer survivors' maintenance of dietary practices and physical activity. 
  • Long-term physical activity outcomes of home-based lifestyle interventions among breast and prostate cancer survivors. 
  • Long-term predictable nipple projection following reconstruction. 
  • Long-term prognostic implications of sex-steroid receptors in human cancer. 
  • Long-term reconstructive outcomes after expander-implant breast reconstruction with serious infectious or wound-healing complications. 
  • Long-term risk of medical conditions associated with breast cancer treatment. 
  • Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. 
  • Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. 
  • Longitudinal predictors of nonadherence to maintenance of mammography. 
  • Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. 
  • Loss of chromosome 8p sequences in human breast carcinoma cell lines. 
  • Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. 
  • Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. 
  • Low incidence of familial breast cancer among Hispanic women. 
  • Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. 
  • Low plasma concentrations of retinol and alpha-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. 
  • Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Luminance and contrast performance of liquid crystal displays for mammographic applications. 
  • Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. 
  • Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. 
  • Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. 
  • Lymphatic mapping and sentinel node analysis: current concepts and applications. 
  • Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. 
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). 
  • Lymphoepithelioma-like carcinoma of the urinary bladder. 
  • Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners. 
  • M6P/IGF2 receptor: a candidate breast tumor suppressor gene. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • MR imaging of ductal carcinoma in situ. 
  • MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. 
  • MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. 
  • MRI predictors of tumor-positive margins after breast-conserving surgery. 
  • Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. 
  • Machine learning-based prediction of future breast cancer using algorithmically measured background parenchymal enhancement on high-risk screening MRI. 
  • Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Magnetic resonance imaging captures the biology of ductal carcinoma in situ. 
  • Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. 
  • Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. 
  • Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. 
  • Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. 
  • Maintenance of p53 alterations throughout breast cancer progression. 
  • Making epidemiologic studies responsive to the needs of participants and communities: the Carolina Breast Cancer Study experience. 
  • Making genuine progress against metastatic breast cancer. 
  • Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. 
  • Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells. 
  • Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. 
  • Malignant lesions initially subjected to short-term mammographic follow-up. 
  • Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. 
  • Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. 
  • Mammography rates 3 years after the 2009 US Preventive Services Task Force Guidelines changes. 
  • Mammography screening behaviors of women exposed prenatally to diethylstilbestrol. 
  • Mammotomography with pinhole incomplete circular orbit SPECT. 
  • Management of breast cancer brain metastases: A practical review. 
  • Management of ductal carcinoma in situ. 
  • Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. 
  • Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. 
  • Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models. 
  • Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. 
  • Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. 
  • Margin Management and Adjuvant Therapy for Phyllodes Tumors: Practice Patterns of the American Society of Breast Surgeons Members. 
  • Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. 
  • Mass detection on mammograms: influence of signal shape uncertainty on human and model observers. 
  • Maximizing sensitivity in medical diagnosis using biased minimax probability machine. 
  • Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. 
  • Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. 
  • Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). 
  • Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. 
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP. 
  • Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. 
  • Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells. 
  • Mediating effects of cancer risk factors on the association between race and cancer incidence: analysis of the NIH-AARP Diet and Health Study. 
  • Medicaid Expansion and Breast Cancer Screening in Appalachia and Non-Appalachia, United States, BRFSS 2003 to 2015. 
  • Medical Facts versus Value Judgments--Toward Preference-Sensitive Guidelines. 
  • Medical Purgatory. 
  • Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors. 
  • Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. 
  • Medullary thyroid carcinoma metastatic to the breast: mammographic appearance. 
  • Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. 
  • Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. 
  • Men's psychological functioning in the context of women's breast cancer. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. 
  • Menopausal hormones and breast cancer in a biracial population. 
  • Mesothelin expression is associated with poor outcomes in breast cancer. 
  • Mesothelin, a novel immunotherapy target for triple negative breast cancer. 
  • Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study. 
  • Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype. 
  • Metabolomics reveals intratumor heterogeneity - Implications for precision medicine. 
  • Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. 
  • Metastatic Merkel cell carcinoma (MCC) of pancreas and breast: a unique case. 
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. 
  • Metastatic breast cancer: Who benefits from surgery? 
  • Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Metastatic lesions arising in a Riedel's lobe. Findings from a sulfur colloid liver-spleen scan. 
  • Methodological challenges in the evaluation of prognostic factors in breast cancer. 
  • Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. 
  • Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues. 
  • MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. 
  • MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells. 
  • Microbial dysbiosis is associated with human breast cancer. 
  • Microscaled proteogenomic methods for precision oncology. 
  • Microscopic localization of calcifications in and around breast carcinoma: a cautionary note for needle core biopsies. 
  • Microtome shaving radiography: demonstration of loss of mammographic microcalcifications during histologic sectioning. 
  • Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine. 
  • Microwave breast imaging: 3-D forward scattering simulation. 
  • Mindful Yoga for women with metastatic breast cancer: design of a randomized controlled trial. 
  • Miniature spectral imaging device for wide-field quantitative functional imaging of the morphological landscape of breast tumor margins. 
  • Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. 
  • Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. 
  • Mobile Health Application for Patients Undergoing Breast Cancer Surgery: Feasibility Study. 
  • Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. 
  • Modeling false positive error making patterns in radiology trainees for improved mammography education. 
  • Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. 
  • Modeling the natural history of ductal carcinoma in situ based on population data. 
  • Modelling the cumulative risk for a false-positive under repeated screening events 
  • Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives. 
  • Modified radical mastectomy with immediate reconstruction for carcinoma of the breast. 
  • Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Modulation of glutathione peroxidase expression by selenium: effect on human MCF-7 breast cancer cell transfectants expressing a cellular glutathione peroxidase cDNA and doxorubicin-resistant MCF-7 cells. 
  • Molecular MRI for sensitive and specific detection of lung metastases. 
  • Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. 
  • Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. 
  • Molecular markers in ductal carcinoma in situ of the breast. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. 
  • Molecular prediction of recurrence of breast cancer. 
  • Molecular sentinel-on-chip for SERS-based biosensing. 
  • Molecular-assisted immunohistochemical optimization. 
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. 
  • Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. 
  • Monoclonal antibodies to antigens abnormally expressed in breast cancer. 
  • Monte Carlo-based inverse model for calculating tissue optical properties. Part II: Application to breast cancer diagnosis. 
  • More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk. 
  • Morphological and biochemical properties of a new human breast cancer cell line. 
  • Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. 
  • Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 
  • Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery: How Low is "Low Risk"? 
  • Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. 
  • Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. 
  • Mucocele-like lesions of the breast - A radiological and clinicopathological analysis. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Multidisciplinary Management of Breast Cancer Brain Metastases. 
  • Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. 
  • Multidisciplinary care of patients with early-stage breast cancer. 
  • Multimodal regulation of E2F1 gene expression by progestins. 
  • Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. 
  • Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. 
  • Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. 
  • Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. 
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. 
  • Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. 
  • Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. 
  • Multiplex detection of breast cancer biomarkers using plasmonic molecular sentinel nanoprobes 
  • Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. 
  • Mutual information-based template matching scheme for detection of breast masses: from mammography to digital breast tomosynthesis. 
  • Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. 
  • Myoepithelial-specific CD44 shedding contributes to the anti-invasive and antiangiogenic phenotype of myoepithelial cells. 
  • N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules. 
  • N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. 
  • NCCN Guidelines Insights Breast Cancer, Version 1.2016. 
  • NCCN Guidelines Insights: Breast Cancer, Version 1.2017. 
  • NCCN Guidelines Insights: Breast Cancer, Version 3.2018. 
  • NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. 
  • NIR-emissive PEG-b-TCL micelles for breast tumor imaging and minimally invasive pharmacokinetic analysis. 
  • NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. 
  • Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. 
  • Nanosensor for in vivo measurement of the carcinogen benzo[a]pyrene in a single cell. 
  • Nanoshell-enabled photonics-based imaging and therapy of cancer. 
  • National Trends and Disparities in Mammography Among Commercially Insured Women, 2001-2010. 
  • National Trends in Immediate Breast Reconstruction: An Analysis of Implant-Based Versus Autologous Reconstruction After Mastectomy. 
  • National trends and predictors of mastectomy with immediate breast reconstruction. 
  • Natural killer cells and lymphocytes increase in women with breast cancer following massage therapy. 
  • Needle aspiration cytology of the irradiated breast. 
  • Needle core biopsy of mammographic lesions. 
  • Negative controls to detect uncontrolled confounding in observational studies of mammographic screening comparing participants and non-participants. 
  • Negative predictive value of breast imaging in patients with palpable lesions. 
  • Negative predictive value of sonography with mammography in patients with palpable breast lesions. 
  • Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis. 
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. 
  • Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • Neoadjuvant chemotherapy in breast cancer: what questions remain? 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. 
  • Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery. 
  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. 
  • Neurotization of the Nipple-Areola Complex during Implant-Based Reconstruction: Evaluation of Early Sensation Recovery. 
  • New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. 
  • New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. 
  • Next-Generation Endocrine Therapies for Breast Cancer. 
  • Nipple sparing mastectomy and microsurgical breast reconstruction: An approach for success. 
  • Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumour-Nipple Distance Less Than 2.0 cm: The Jury is Still Out. 
  • Nipple-sparing mastectomy: A review of outcomes at a single institution. 
  • Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. 
  • Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. 
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 
  • Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. 
  • Node biopsy vs. full lymph node dissection for breast cancer. 
  • Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 
  • Non-communicable chronic diseases and timely breast cancer screening among women of the Eastern Caribbean Health Outcomes Research Network (ECHORN) Cohort Study. 
  • Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients. 
  • Non-invasive, quantitative monitoring of hyperthermia-induced EGFR activation in xenograft tumours. 
  • Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. 
  • Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. 
  • Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. 
  • Nonparametric inference on median residual life function. 
  • Nonsurgical approach in stage I and stage II breast cancer. 
  • Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. 
  • Normal Axillary Lymph Node Variability Between White and Black Women on Breast MRI. 
  • Not all negative emotions are equal: the role of emotional expression in online support groups for women with breast cancer. 
  • Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. 
  • Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. 
  • Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. 
  • Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. 
  • Novel--and "neu"--therapeutic possibilities for heart failure. 
  • Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. 
  • Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. 
  • Nuclear deformation during breast cancer cell transmigration. 
  • Nurses' Role in Providing Comprehensive Communication, Prognostication, and Palliative Care During the COVID-19 Pandemic. 
  • OP449 inhibits breast cancer growth without adverse metabolic effects. 
  • OPRM1 receptor as new biomarker to help the prediction of post mastectomy pain and recurrence in breast cancer. 
  • Obesity and body fat distribution and breast cancer prognosis. 
  • Obesity and mortality after locoregional breast cancer diagnosis. 
  • Obesity, body fat distribution, and sex hormones in breast cancer patients. 
  • Obesity, cholesterol metabolism, and breast cancer pathogenesis. 
  • Obesity, non-protein-bound estradiol levels, and distribution of estradiol in the sera of breast cancer patients. 
  • Observations of tissue response to acoustic radiation force: opportunities for imaging. 
  • Observer detection limits for a dedicated SPECT breast imaging system. 
  • Ocular toxicity following high dose chemotherapy and autologous transplant. 
  • Of medicine and the breast. 
  • Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). 
  • Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review. 
  • Omission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care. 
  • On Enrichment Strategies for Biomarker Stratified Clinical Trials. 
  • On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. 
  • Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. 
  • Oncogenic pathway signatures in human cancers as a guide to targeted therapies. 
  • Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. 
  • Oncologic Safety of Nipple-Sparing Mastectomy in Women with Breast Cancer. 
  • Oncologic image compression using both wavelet and masking techniques. 
  • Oncoplastic surgery: fashion or necessity? 
  • One disease, two lives. 
  • Opioid Use Disorder and Overdose in Older Adults With Breast, Colorectal, or Prostate Cancer. 
  • Opioid prescribing exceeds consumption following common surgical oncology procedures. 
  • Opportunities to Improve Detection and Treatment of Depression Among Patients With Breast Cancer Treated in an Integrated Delivery System. 
  • Optical Imaging of Glucose Uptake and Mitochondrial Membrane Potential to Characterize Her2 Breast Tumor Metabolic Phenotypes. 
  • Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. 
  • Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast. 
  • Optical nanosensors for detecting proteins and biomarkers in individual living cells. 
  • Optical sensor for the detection of caspase-9 activity in a single cell. 
  • Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins. 
  • Optimism, social support, and adjustment in African American women with breast cancer. 
  • Optimized approach to decision fusion of heterogeneous data for breast cancer diagnosis. 
  • Optimized image acquisition for breast tomosynthesis in projection and reconstruction space. 
  • Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy? 
  • Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. 
  • Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. 
  • Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute. 
  • Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. 
  • Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. 
  • Oral contraceptive use and risk of cancer--response. 
  • Oral contraceptives and breast cancer among African-american women and white women. 
  • Oral contraceptives and breast cancer: a case-control study with hospital and community controls. 
  • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. 
  • Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. 
  • Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. 
  • Orbital metastasis in inflammatory breast cancer. 
  • Orbital phlebography in the study of cavernous sinus disease. 
  • Ordered subset analysis in genetic linkage mapping of complex traits. 
  • Organization of the human aromatase p450 (CYP19) gene. 
  • Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. 
  • Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. 
  • Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. 
  • Osteopontin-targeted probe detects orthotopic breast cancers using optoacoustic imaging. 
  • Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. 
  • Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. 
  • Outcomes and Costs for Women After Breast Cancer: Preparing for Improved Survivorship of Medicare Beneficiaries. 
  • Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. 
  • Outcomes of an uncertainty management intervention in younger African American and Caucasian breast cancer survivors. 
  • Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer. 
  • Overestimation of test effects in clinical judgment. 
  • Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. 
  • Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. 
  • Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. 
  • Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. 
  • Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. 
  • Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. 
  • Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. 
  • Oxidatively modified proteins as plasma biomarkers in breast cancer. 
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 
  • PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. 
  • PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. 
  • PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • PTSD diagnoses, subsyndromal symptoms, and comorbidities contribute to impairments for breast cancer survivors. 
  • Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. 
  • Paget's disease of the breast masquerading as squamous cell carcinoma on cytology: a case report. 
  • Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Management-American Society of Breast Surgeons Opioid/Pain Control Workgroup. 
  • Pain, depressive symptoms, and self-efficacy for pain management: examination in African-American women with breast cancer. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. 
  • Papillary carcinoma of the breast: imaging findings. 
  • Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. 
  • Paradoxical relationship between chromosomal instability and survival outcome in cancer. 
  • Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. 
  • Paravertebral block for breast cancer surgery. 
  • Paravertebral blockade for modified radical mastectomy in a pregnant patient. 
  • Paravertebral somatic nerve blocks for breast surgery in a patient with hypertrophic obstructive cardiomyopathy. 
  • Parc-ing p53 in the cytoplasm. 
  • Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. 
  • Participation rates in a case-control study: the impact of age, race, and race of interviewer. 
  • Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. 
  • Partnering with engaged patients accelerates research. 
  • Partners in Crime: Neutrophil-CTC Collusion in Metastasis. 
  • Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. 
  • Pathogenesis of radiation-induced capsular contracture in tissue expander and implant breast reconstruction. 
  • Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. 
  • Pathologic considerations in the high-risk breast patient. 
  • Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. 
  • Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. 
  • Patient Anxiety Before and Immediately After Imaging-Guided Breast Biopsy Procedures: Impact of Radiologist-Patient Communication. 
  • Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. 
  • Patient Perceptions of Breast Cancer Risk in Imaging-Detected Low-Risk Scenarios and Thresholds for Desired Intervention: A Multi-Institution Survey. 
  • Patient Perspectives on the Financial Costs and Burdens of Breast Cancer Surgery. 
  • Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. 
  • Patient and Radiologist Demographics Influence Perceptions of Screening Mammography Reports. 
  • Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. 
  • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. 
  • Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. 
  • Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients. 
  • Patient anxiety before and immediately after imaging-guided breast biopsy procedures: impact of radiologist-patient communication. 
  • Patient compliance in mobile screening mammography. 
  • Patient experience and attitudes toward addressing the cost of breast cancer care. 
  • Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. 
  • Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy. 
  • Patient-Reported Outcomes of Breast Reconstruction: Does the Quality of Decisions Matter? 
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. 
  • Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. 
  • Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. 
  • Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. 
  • Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. 
  • Patient-reported outcomes in the Translational Breast Cancer Research Consortium. 
  • Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. 
  • Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer. 
  • Patient-reported upper extremity outcome measures used in breast cancer survivors: a systematic review. 
  • Patterns of breast magnetic resonance imaging use: an opportunity for data-driven resource allocation. 
  • Patterns of chromosomal alterations in breast ductal carcinoma in situ. 
  • Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset. 
  • Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors. 
  • Patterns of occurrence of second primary non-mammary malignancies in breast cancer patients: results from 1382 consecutive autopsies. 
  • Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. 
  • Pediatric phyllodes tumors: A review of the National Cancer Data Base and adherence to NCCN guidelines for phyllodes tumor treatment. 
  • Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. 
  • Pegfilgrastim: the promise of pegylation fulfilled. 
  • Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • PenPC: A two-step approach to estimate the skeletons of high-dimensional directed acyclic graphs. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Perceived breast cancer risk: Heuristic reasoning and search for a dominance structure 
  • Perceptron error surface analysis: a case study in breast cancer diagnosis. 
  • Performance assessment for radiologists interpreting screening mammography. 
  • Performance metrics of an optical spectral imaging system for intra-operative assessment of breast tumor margins. 
  • Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. 
  • Performance of preoperative breast MRI based on breast cancer molecular subtype. 
  • Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth. 
  • Perifosine as a potential novel anti-telomerase therapy. 
  • Perinatal Considerations in Women With Previous Diagnosis of Cancer. 
  • Peritumoral expression of adipokines and fatty acids in breast cancer. 
  • Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). 
  • Persistent Breast Pain Among Women With Histories of Breast-conserving Surgery for Breast Cancer Compared With Women Without Histories of Breast Surgery or Cancer. 
  • Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress. 
  • Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance). 
  • Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. 
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. 
  • Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. 
  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. 
  • Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. 
  • Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. 
  • Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. 
  • Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. 
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. 
  • Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. 
  • Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. 
  • Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. 
  • Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. 
  • Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. 
  • Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. 
  • Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. 
  • Phase I study of Doxil and vinorelbine in metastatic breast cancer. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. 
  • Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. 
  • Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer. 
  • Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. 
  • Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. 
  • Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. 
  • Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. 
  • Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. 
  • Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. 
  • Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis. 
  • Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. 
  • Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis. 
  • Photodynamic therapy for chest wall recurrence in breast cancer. 
  • Physical activity at age 12 and adult breast cancer risk (United States). 
  • Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. 
  • Physician-related barriers to breast cancer screening in older women. 
  • Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. 
  • Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science. 
  • Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. 
  • Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. 
  • Plasma carotenoids, retinol, and tocopherols and postmenopausal breast cancer risk in the Multiethnic Cohort Study: a nested case-control study. 
  • Plasmonics nanoprobes: detection of single-nucleotide polymorphisms in the breast cancer BRCA1 gene. 
  • Point-counterpoint: soy intake for breast cancer patients. 
  • Point/Counterpoint. Cone beam x-ray CT will be superior to digital x-ray tomosynthesis in imaging the breast and delineating cancer. 
  • Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence. 
  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. 
  • Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). 
  • Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. 
  • Polygenic risk modeling for prediction of epithelial ovarian cancer risk. 
  • Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model. 
  • Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. 
  • Polymorphism and altered methylation of the lactoferrin gene in normal leukocytes, leukemic cells, and breast cancer. 
  • Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women  
  • Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. 
  • Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 
  • Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 
  • Population and target considerations for triple-negative breast cancer clinical trials. 
  • Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. 
  • Positive and negative mood following imaging-guided core needle breast biopsy and receipt of biopsy results. 
  • Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. 
  • Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome. 
  • Post-Mastectomy Imaging after Breast Reconstruction: In Reply to Gordon. 
  • Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. 
  • Post-mastectomy radiation in large node-negative breast tumors: does size really matter? 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Post-surgical events and persistent pain after breast cancer surgery: a reply. 
  • Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. 
  • Postmastectomy Conundrum. 
  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 
  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 
  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 
  • Postmenopausal hormone replacement therapy. Information for effective patient counseling. 
  • Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3'-untranslated region of tumor necrosis factor-alpha messenger RNA. 
  • Posttraumatic growth and health-related quality of life in a racially diverse cohort of breast cancer survivors. 
  • Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing. 
  • Potential Use of American College of Radiology BI-RADS Mammography Atlas for Reporting and Assessing Lesions Detected on Dedicated Breast CT Imaging: Preliminary Study. 
  • Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. 
  • Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. 
  • Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. 
  • Pre-counseling education materials for BRCA testing: does tailoring make a difference? 
  • Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. 
  • Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. 
  • Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. 
  • Preclinical assessment of comfort and secure fit of thermobrachytherapy surface applicator (TBSA) on volunteer subjects. 
  • Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. 
  • Prediagnostic serum vitamin D and breast cancer. 
  • Predictable Location of Breast Sensory Nerves for Breast Reinnervation. 
  • Predicting Upstaging of DCIS to Invasive Disease: Radiologists's Predictive Performance. 
  • Predicting a local recurrence after breast-conserving therapy by gene expression profiling. 
  • Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. 
  • Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features. 
  • Predicting error in detecting mammographic masses among radiology trainees using statistical models based on BI-RADS features. 
  • Predicting negative mood state and personal growth in African American and White long-term breast cancer survivors. 
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. 
  • Predicting the clinical status of human breast cancer by using gene expression profiles. 
  • Predicting the cumulative risk of false-positive mammograms. 
  • Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. 
  • Prediction of Upstaged Ductal Carcinoma In Situ Using Forced Labeling and Domain Adaptation. 
  • Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features. 
  • Prediction of breast cancer malignancy using an artificial neural network. 
  • Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. 
  • Predictors of Response to an Evidence-Based Behavioral Cancer Pain Management Intervention: An Exploratory Analysis From a Clinical Trial. 
  • Predictors of adoption of mammography in women under age 50. 
  • Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. 
  • Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. 
  • Predictors of pain experienced by women during percutaneous imaging-guided breast biopsies. 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. 
  • Preference weights for chemotherapy side effects from the perspective of women with breast cancer. 
  • Preliminary efficacy of a lovingkindness meditation intervention for patients undergoing biopsy and breast cancer surgery: A randomized controlled pilot study. 
  • Premenopausal gynecologic surgery and survival among black and white women with breast cancer. 
  • Prenatal diethylstilbestrol exposure and cancer risk in women. 
  • Preoperative Body Image Factors Are Associated with Complications after Breast Reconstruction. 
  • Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. 
  • Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. 
  • Preoperative breast size affects reconstruction status following mastectomy. 
  • Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. 
  • Presence of leptin in breast cell lines and breast tumors. 
  • Prevalence and impact of correlative science in breast cancer phase II trials. 
  • Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. 
  • Primary Breast Neuroendocrine Tumor. 
  • Primary primitive neuroectodermal tumor of the breast. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Primary systemic therapy in breast cancer: past lessons and new approaches. 
  • Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer. 
  • Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. 
  • Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. 
  • Prioritization of research addressing management strategies for ductal carcinoma in situ. 
  • Probabilistic computer model developed from clinical data in national mammography database format to classify mammographic findings. 
  • Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. 
  • Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. 
  • Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 
  • Proceedings: Measurement of endogenous steroid levels in human breast tumours by mass fragmentography. 
  • Progesterone promotes immunomodulation and tumor development in the murine mammary gland. 
  • Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. 
  • Progesterone receptor membrane component 1: is metabolism integral to its function and what other steroids are involved? 
  • Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. 
  • Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. 
  • Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. 
  • Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. 
  • Prognostic factors in the initial response to therapy by patients with advanced breast cancer. 
  • Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer. 
  • Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. 
  • Prognostic significance of reactivation of telomerase in breast core biopsy specimens. 
  • Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative breast carcinoma. 
  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. 
  • Progress in breast cancer-can we do better? 
  • Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. 
  • Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. 
  • Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study. 
  • Promoting community practitioners' use of evidence-based approaches to increase breast cancer screening. 
  • Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. 
  • Prone table stereotactic breast biopsy: facilitating biopsy of posterior lesions using the arm-through-the-hole technique. 
  • Propensity score weighting with multilevel data. 
  • Prophylactic mastectomy in women with a high risk of breast cancer. 
  • Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials. 
  • Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. 
  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. 
  • Prospective study of factors predicting adherence to surveillance mammography in women treated for breast cancer. 
  • Prospective trial of a video educational tool for radiation oncology patients. 
  • Prospective, Randomized, Controlled Comparison of Bupivacaine versus Liposomal Bupivacaine for Pain Management after Unilateral Delayed Deep Inferior Epigastric Perforator Free Flap Reconstruction. 
  • Prostate-derived Ets factor, an oncogenic driver in breast cancer. 
  • Protecting Confidentiality in Cancer Registry Data With Geographic Identifiers. 
  • Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. 
  • Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. 
  • Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. 
  • Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. 
  • Proteome-Wide Characterization of Phosphorylation-Induced Conformational Changes in Breast Cancer. 
  • Proton therapy for the treatment of inflammatory breast cancer. 
  • Provider characteristics and mammography recommendation among women in their 40s and 50s. 
  • Pruritus in patients with solid tumors: an overlooked supportive care need. 
  • Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. 
  • Psychological adjustment among African American breast cancer patients: one-year follow-up results of a randomized psychoeducational group intervention. 
  • Psychological distress and quality of life associated with genetic testing for breast cancer risk. 
  • Psychological impact of diagnosis and risk reduction among cancer survivors. 
  • Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. 
  • Psychometric evaluation of the Brief Cancer Impact Assessment among breast cancer survivors. 
  • Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. 
  • Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. 
  • Psychosocial issues confronting young women with breast cancer. 
  • Publishing web-based guidelines using interactive decision models. 
  • Pulmonary changes after primary irradiationfor early breast carcinoma. 
  • Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. 
  • Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. 
  • Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. 
  • Quality of Patient Decisions About Breast Reconstruction After Mastectomy. 
  • Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). 
  • Quality of life after adjuvant chemotherapy for breast cancer. 
  • Quality of life after breast cancer diagnosis and survival. 
  • Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Quality of life changes during the pre- to postdiagnosis period and treatment-related recovery time in older women with breast cancer. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • Quantifying the effect of intrafraction motion during breast IMRT planning and dose delivery. 
  • Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancer. 
  • Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. 
  • Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density. 
  • Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. 
  • Quantitative breast tomosynthesis: from detectability to estimability. 
  • Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo. 
  • Quantitative spectral reflectance imaging device for intraoperative breast tumor margin assessment. 
  • Quantity of Resistance Exercise for Breast Cancer Patients: Does the Dose Match the Objective? 
  • RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation. 
  • RCT of a psychological intervention for patients with cancer: I. mechanisms of change. 
  • RGS-GAIP-interacting protein controls breast cancer progression. 
  • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. 
  • Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. 
  • Race, anthropometric factors, and stage at diagnosis of breast cancer. 
  • Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 
  • Race-Related Differences in the Clinical Presentation and Histopathologic Features of Phyllodes Tumor. 
  • Race-associated biological differences among Luminal A breast tumors. 
  • Race/ethnicity and socio-economic differences in breast cancer surgery outcomes. 
  • Race/ethnicity, physical activity, and quality of life in breast cancer survivors. 
  • Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. 
  • Racial and Ethnic Disparities in Surgical Outcomes after Postmastectomy Breast Reconstruction. 
  • Racial and ethnic differences in adjuvant hormonal therapy use. 
  • Racial and socio-economic disparities in breast cancer hospitalization outcomes by insurance status. 
  • Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. 
  • Racial differences in enrolment in a cancer genetics registry. 
  • Racial differences in follow-up of abnormal mammography findings among economically disadvantaged women. 
  • Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. 
  • Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. 
  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. 
  • Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. 
  • Racial-ethnic variations in phyllodes tumors among a multicenter United States cohort. 
  • Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. 
  • Radiation Dermatitis: A Prevention Protocol for Patients With Breast Cancer. 
  • Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. 
  • Radiation dosimetry in digital breast tomosynthesis: report of AAPM Tomosynthesis Subcommittee Task Group 223. 
  • Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. 
  • Radiation-Induced Angiosarcoma after Breast-Cancer Treatment. 
  • Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study. 
  • Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study. 
  • Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. 
  • Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. 
  • Radiologist-Patient Communication: Current Practices and Barriers to Communication in Breast Imaging. 
  • Radiology resident mammography training: interpretation difficulty and error-making patterns. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Radiotherapy after mastectomy. 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. 
  • Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. 
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. 
  • Randomized trial of hyperthermia and radiation for superficial tumors. 
  • Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. 
  • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. 
  • Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Rapid determination of oxygen saturation and vascularity for cancer detection. 
  • Rapid noninvasive optical imaging of tissue composition in breast tumor margins. 
  • Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. 
  • Rapid staining and imaging of subnuclear features to differentiate between malignant and benign breast tissues at a point-of-care setting. 
  • Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. 
  • Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland. 
  • Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients. 
  • Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. 
  • Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. 
  • Rationale for immediate reconstruction of the breast following modified radical mastectomy. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Re: Breast cancer mortality among female electrical workers in the United States. 
  • Re: KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer (Int J Cancer 123: 2239-2246, 2008). 
  • Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. 
  • Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. 
  • Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. 
  • Receptor discordance in breast cancer brain metastases: when knowledge is power. 
  • Recombinant polyclonal antibody libraries. 
  • Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. 
  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 
  • Reconstruction with vascularized composite tissue in patients with excessive injury following surgery and irradiation. 
  • Recruiting older women for screening mammography. 
  • Recurrence after mastectomy for ductal carcinoma in situ. 
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. 
  • Recurrence risk and margin status in granular cell tumors of the breast: a clinicopathologic study of 13 patients. 
  • Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms. 
  • Recurrent ductal carcinoma in situ after total mastectomy. 
  • Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. 
  • Reduced Mammography Screening for Breast Cancer among Women with Visual Impairment. 
  • Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y. 
  • Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. 
  • Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. 
  • Reframing the conversation about contralateral prophylactic mastectomy: Preparing women for postsurgical realities. 
  • Regional Nodal Irradiation in the Modern Era of Breast Cancer Management. 
  • Regional lung density changes after radiation therapy for tumors in and around thorax. 
  • Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. 
  • Regression on quantile residual life. 
  • Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. 
  • Reimagine: a randomized controlled trial of an online, symptom self-management curriculum among breast cancer survivors. 
  • Relating radiation-induced regional lung injury to changes in pulmonary function tests. 
  • Relation between p53 overexpression and established prognostic factors in breast cancer. 
  • Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk. 
  • Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study. 
  • Relationship between histopathology and in vitro clonogenicity in breast cancer. 
  • Relationship between social support, physical symptoms, and depression in women with breast cancer and pain. 
  • Relationship between tamoxifen use and high risk endometrial cancer histologic types. 
  • Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. 
  • Relationship of epithelial ovarian cancer to other malignancies within families. 
  • Relationships Between MRI Breast Imaging-Reporting and Data System (BI-RADS) Lexicon Descriptors and Breast Cancer Molecular Subtypes: Internal Enhancement is Associated with Luminal B Subtype. 
  • Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer. 
  • Relationships among breast cancer perceived absolute risk, comparative risk, and worries. 
  • Relationships among objective and subjective risk for breast cancer and mammography stages of change. 
  • Reliability analysis framework for computer-assisted medical decision systems. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Reminders of cancer risk and pain catastrophizing: relationships with cancer worry and perceived risk in women with a first-degree relative with breast cancer. 
  • Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. 
  • Reoperation for Margins After Breast Conservation Surgery: What's Old Is New Again. 
  • Repair of mitomycin C cross-linked DNA in mammalian cells measured by a host cell reactivation assay. 
  • Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach. 
  • Reply to "Conventional Ductography Combined With Digital Breast Tomosynthesis for Imaging of Pathologic Nipple Discharge". 
  • Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'. 
  • Reply to L.B. Marks et al. 
  • Reply to: 'Liposuction-assisted brachioplasty in breast cancer-related lymphedema: Impact on volume reduction and quality of life'. 
  • Reply: "age at menopause: imputing age at menopause for women with a hysterectomy with application to risk of postmenopausal breast cancer". 
  • Reply: Antibiotic Prophylaxis following Implant-Based Breast Reconstruction: What Is the Evidence? 
  • Reply: Breast Cancer and Reconstruction: Normative Data for Interpreting the BREAST-Q. 
  • Reply: The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients: A Propensity-Matched Analysis. 
  • Reporting fine-needle aspirates of breast: a survey of preferences among surgeons. 
  • Reporting of race and ethnicity in breast cancer research: room for improvement. 
  • Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. 
  • Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay. 
  • Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. 
  • Reproducible and efficient technique for performing a sensory nerve sparing mastectomy: Lessons learned from cadaveric and patient dissections. 
  • Reproductive factors and breast cancer risk among older women. 
  • Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States). 
  • Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. 
  • Repurposing the Mammographic Breast Density Category for Predicting Lymphedema Risk in Patients With Breast Cancer. 
  • Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. 
  • Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial. 
  • Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. 
  • Residential environment and breast cancer incidence and mortality: a systematic review and meta-analysis. 
  • Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. 
  • Resistance to hydrogen peroxide associated with altered catalase mRNA stability in MCF7 breast cancer cells. 
  • Response to Dekker, Stege, and Versteeg. 
  • Response to Letter to the Editor: Vitamin D status may help explain racial disparities in breast cancer hospitalization outcomes. 
  • Response to Strassels and Durham. 
  • Response to reader reaction. 
  • Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. 
  • Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer. 
  • Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. 
  • Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. 
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. 
  • Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. 
  • Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. 
  • Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. 
  • Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration. 
  • Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300. 
  • Retinopathy and optic neuropathy after transplantation. 
  • Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. 
  • Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. 
  • Retroviral gene transduction of circulating progenitor cells in patients with metastatic breast cancer. 
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. 
  • Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. 
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 
  • Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. 
  • Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. 
  • Risk factors for estrogen receptor-positive breast cancer. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for persistent pain after breast cancer surgery: a multicentre prospective cohort study. 
  • Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study. 
  • Risk factors for surgical site infections after breast surgery: a systematic review and meta-analysis. 
  • Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. 
  • Risk of invasive breast cancer and ductal carcinoma in situ in women with atypical papillary lesions of the breast. 
  • Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. 
  • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. 
  • Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. 
  • Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer. 
  • Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. 
  • Role of TGF-β receptor III localization in polarity and breast cancer progression. 
  • Role of digital breast tomosynthesis in the evaluation of focal breast pain. 
  • Role of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration. 
  • Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. 
  • Role of self-efficacy for pain management and pain catastrophizing in the relationship between pain severity and depressive symptoms in women with breast cancer and pain. 
  • Routine use of zoledronic acid in early-stage breast cancer. 
  • Rural-urban differences in health behaviors and outcomes among older, overweight, long-term cancer survivors in the RENEW randomized control trial. 
  • S-nitrosylation of Ras in breast cancer. 
  • SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. 
  • SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. 
  • STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. 
  • Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. 
  • Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. 
  • Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis. 
  • Sample size and power calculation for molecular biology studies. 
  • Score and deviance residuals based on the full likelihood approach in survival analysis. 
  • Screening and early detection among racial and ethnic minority women. 
  • Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Screening breast MR imaging in women with a history of chest irradiation. 
  • Screening experiments and the use of fractional factorial designs in behavioral intervention research. 
  • Screening for Breast Cancer in Average-Risk Women. 
  • Screening for lung cancer: been there and done that. 
  • Screening mammography and Pap tests among older American women 1996-2000: results from the Health and Retirement Study (HRS) and Asset and Health Dynamics Among the Oldest Old (AHEAD). 
  • Screening mammography at 40-49 years: regret or no regret? 
  • Screening mammography for average-risk women. 
  • Screening mammography use in older women according to health status: a systematic review and meta-analysis. 
  • Second international workshop on monoclonal antibodies and breast cancer. San Francisco, November 20-21, 1986. 
  • Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Segmentation of suspicious clustered microcalcifications in mammograms. 
  • Selecting cases for whom additional tests can improve prognostication. 
  • Selection of patients for heterotopic implantation of the areola and nipple. 
  • Selection of treatment among Latina and non-Latina white women with ductal carcinoma in situ. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. 
  • Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. 
  • Self reported morbidity and awareness regarding common cancers in elderly women. 
  • Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. 
  • Self-help on-line: an outcome evaluation of breast cancer bulletin boards. 
  • Self-organizing map for cluster analysis of a breast cancer database. 
  • Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study. 
  • Sensory Restoration in Abdominally Based Free Flaps for Breast Reconstruction Using Nerve Allograft. 
  • Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. 
  • Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. 
  • Separate cavity margin sampling at the time of initial breast lumpectomy significantly reduces the need for reexcisions. 
  • Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. 
  • Sequential matched analysis of racial disparities in breast cancer hospitalization outcomes among African American and White patients. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. 
  • Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. 
  • Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. 
  • Serum cholesterol reduction with tamoxifen. 
  • Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. 
  • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 
  • Sex steroid receptor concentration in breast carcinoma tissue: effect of devascularization during mastectomy. 
  • Sexual concerns in cancer patients: a comparison of GI and breast cancer patients. 
  • Sexual dysfunction and reproductive concerns in young women with breast cancer: Type, prevalence, and predictors of problems. 
  • Shared heritability and functional enrichment across six solid cancers. 
  • Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. 
  • Should New "No Ink On Tumor" Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. 
  • Signet-ring cells in the bone marrow as an indication of cryptic metastasis of breast carcinoma: A case report. 
  • Silicone controversy: a survey of women with breast cancer and silicone implants. 
  • Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. 
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. 
  • Simulation based evaluation of a fan beam coded aperture x-ray diffraction imaging system for biospecimen analysis. 
  • Simulation of mammographic lesions. 
  • Simulation study of a quasi-monochromatic beam for x-ray computed mammotomography. 
  • Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging. 
  • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. 
  • Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis. 
  • Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. 
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. 
  • Skin metastases confined to a field of previous irradiation. Report of two cases and review of the literature. 
  • Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. 
  • Sleep disorder diagnoses and clinical outcomes among hospitalized breast cancer patients: a nationwide inpatient sample study. 
  • Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life. 
  • Smoothing spline-based score tests for proportional hazards models. 
  • Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. 
  • Social comparisons predict health-related quality of life and depressive symptoms across the first year of breast cancer treatment. 
  • Social relationships and their associations with affective symptoms of women with breast cancer: A scoping review. 
  • Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). 
  • Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. 
  • Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. 
  • Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. 
  • Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the World Health Survey. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Somatic Mutations in LRRK2 Identify a Subset of Invasive Mammary Carcinomas Associated with High Mutation Burden. 
  • Sonographic detection and sonographically guided biopsy of breast microcalcifications. 
  • Sonographically guided biopsy of suspicious microcalcifications of the breast: a pilot study. 
  • Sonography of solid breast lesions: observer variability of lesion description and assessment. 
  • Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. 
  • Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis. 
  • Spatiotemporal strategies to identify aggressive biology in precancerous breast biopsies. 
  • Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma. 
  • Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. 
  • Spectral domain phase microscopy for local measurements of cytoskeletal rheology in single cells. 
  • Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. 
  • Standardized versus open-ended assessment of psychosocial and medical concerns among African American breast cancer patients. 
  • Starting with the ABCs: Akt in breast cancer. 
  • Stereoscopically guided characterization of three-dimensional dynamic MR images of the breast. 
  • Stereotactic biopsy of noncalcified breast lesions: utility of vacuum-assisted technique compared to multipass automated gun technique. 
  • Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? 
  • Stereotactic breast biopsy of noncalcified lesions: a cost-minimization analysis comparing 14-gauge multipass automated core biopsy to 14- and 11-gauge vacuum-assisted biopsy. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. 
  • Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 
  • Streaming detection for evaluation of indeterminate sonographic breast masses: a pilot study. 
  • Stress buffering effects of daily spousal support on women's daily emotional and physical experiences in the context of breast cancer concerns. 
  • Stress, coping, and circadian disruption among women awaiting breast cancer surgery. 
  • Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. 
  • Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. 
  • Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). 
  • Subjective and objective evaluation of breast temperature following post-mastectomy reconstruction. 
  • Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. 
  • Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Supporting statements and rationale. 
  • Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. 
  • Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. 
  • Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair. 
  • Surgeon choice in the use of postdischarge antibiotics for prophylaxis following mastectomy with and without breast reconstruction. 
  • Surgery for palliation and treatment of advanced breast cancer. 
  • Surgery of the primary tumor does not improve survival in stage IV breast cancer. 
  • Surgery or ablative radiotherapy for breast cancer oligometastases. 
  • Surgical Dead End in a Renal Transplant Recipient Associated With a Rare Thrombohemorrhagic Syndrome. 
  • Surgical Management of the Axilla in Elderly Women With Node-Positive Breast Cancer. 
  • Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. 
  • Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. 
  • Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. 
  • Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. 
  • Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ. 
  • Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. 
  • Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer. 
  • Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. 
  • Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. 
  • Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy. 
  • Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors. 
  • Suspicious breast lesions detected at 3.0 T magnetic resonance imaging: clinical and histological outcomes. 
  • Suspicious mammographic masses in the breast: splenosis in an unusual body site due to a remote ballistic trauma. 
  • Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment. 
  • Symptomatic cardiac events following radiation therapy for left-sided breast cancer: possible association with radiation therapy-induced changes in regional perfusion. 
  • Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. 
  • Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. 
  • Synchronous primary carcinoma of breast and ovary versus ovarian metastases. 
  • Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. 
  • Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: A retrospective cohort study. 
  • Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. 
  • Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. 
  • Synthesis and characterization of SERS gene probe for BRCA-1 (breast cancer). 
  • Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. 
  • Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. 
  • Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. 
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. 
  • Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. 
  • Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. 
  • Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. 
  • Systemic management of brain metastases in HER2+ breast cancer in 2022. 
  • Systemic therapy for older women with breast cancer. 
  • T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. 
  • TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. 
  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. 
  • TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. 
  • TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. 
  • TNF-alpha levels in cancer patients relate to social variables. 
  • Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 
  • Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Tamoxifen in postmenopausal women a safety perspective. 
  • Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • Tamoxifen versus aromatase inhibitors for breast cancer prevention. 
  • Tamoxifen versus surgery in elderly patients with breast cancer. 
  • Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. 
  • Targeted breast re-innervation (TBR) for post-mastectomy pain. 
  • Targeted therapies for cancer 2004. 
  • Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. 
  • Targeting mutant estrogen receptors. 
  • Targeting risk factors for reducing the racially disparate burden in breast cancer. 
  • Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. 
  • Technical considerations in nonreconstructive mastectomy patients. 
  • Technology evaluation: Theratope, Biomira Inc. 
  • Teenage acne and cancer risk in US women: A prospective cohort study. 
  • Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. 
  • Telomerase activity and prognosis in primary breast cancers. 
  • Telomerase activity in ductal carcinoma in situ and invasive breast cancer. 
  • Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). 
  • Testing for hereditary breast and ovarian cancer in the southeastern United States. 
  • Testing whether decision aids introduce cognitive biases: results of a randomized trial. 
  • Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus. 
  • Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. 
  • The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer. 
  • The "banked" TRAM: a method to insure mastectomy skin-flap survival. 
  • The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer. 
  • The Association of Overall Annual Hospital Volume and Perioperative Outcomes following Free Flap Breast Reconstruction. 
  • The Association of Self-esteem With Caregiving Demands, Coping, Burden, and Health Among Caregivers of Breast Cancer Patients: A Structural Equation Modeling Approach. 
  • The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). 
  • The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. 
  • The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. 
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors. 
  • The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. 
  • The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). 
  • The Diet Quality Index-Revised: a tool to promote and evaluate dietary change among older cancer survivors enrolled in a home-based intervention trial. 
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. 
  • The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. 
  • The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. 
  • The Effect of Hospital Volume on Breast Cancer Mortality. 
  • The Effect of Lavender Oil on Perioperative Pain, Anxiety, Depression, and Sleep after Microvascular Breast Reconstruction: A Prospective, Single-Blinded, Randomized, Controlled Trial. 
  • The Effects of 16 Weeks of Exercise Training on Neutrophil Functions in Breast Cancer Survivors. 
  • The Effects of Surgery Type and Chemotherapy on Early-Stage Breast Cancer Patients' Quality of Life Over 2-Year Follow-up. 
  • The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. 
  • The Evolution of Breast Satisfaction and Well-Being after Breast Cancer: A Propensity-Matched Comparison to the Norm. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. 
  • The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. 
  • The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins. 
  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. 
  • The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. 
  • The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients: A Propensity-Matched Analysis. 
  • The Impact of Education and Prescribing Guidelines on Opioid Prescribing for Breast and Melanoma Procedures. 
  • The Impact of Set-Up Uncertainty on Dose-Response Estimates. 
  • The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. 
  • The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). 
  • The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions. 
  • The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions. 
  • The Influence of Fat Grafting on Breast Imaging after Postmastectomy Reconstruction: A Matched Cohort Analysis. 
  • The Influence of Marital Status on Contemporary Patterns of Postmastectomy Breast Reconstruction. 
  • The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. 
  • The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. 
  • The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment. 
  • The Necessity of the Nipple: Redefining Completeness in Breast Reconstruction. 
  • The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. 
  • The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. 
  • The Ras-related protein AGS1/RASD1 suppresses cell growth. 
  • The Texas Breast Screening Project: Part I. Mammographic and clinical results. 
  • The Texas Breast Screening Project: Part II. Demographics, risk profiles, and health practices of participants. 
  • The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. 
  • The anatomy of missed breast cancers. 
  • The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. 
  • The association of early life socioeconomic position on breast cancer incidence and mortality: a systematic review. 
  • The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. 
  • The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. 
  • The association of polymorphisms of CDT1 and GMNN gene with the risk of breast cancer in Chinese women: a case-control analysis. 
  • The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). 
  • The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. 
  • The benefits of discussing adjuvant therapies one at a time instead of all at once. 
  • The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. 
  • The cancer translational research informatics platform. 
  • The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes. 
  • The choice for breast cancer surgery: can women accurately predict postoperative quality of life and disease-related stigma? 
  • The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The complexity of chronic disease at later ages: practical implications for prospective payment and data collection. 
  • The current clinical value of the DCIS Score. 
  • The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. 
  • The diagnostic accuracy/efficacy of MRI in differentiating hepatic hemangiomas from metastatic colorectal/breast carcinoma: a multiple reader ROC analysis using a jackknife technique. 
  • The distinct role of comparative risk perceptions in a breast cancer prevention program. 
  • The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • The effect of comorbid illness on receipt of cancer screening by older people. 
  • The effect of data sampling on the performance evaluation of artificial neural networks in medical diagnosis. 
  • The effect of patient-specific factors on radiation-induced regional lung injury. 
  • The effect of physician characteristics and their practice environment on surgical referral patterns for early-stage breast cancer in Iowa. 
  • The effect of sarcopenia on perioperative complications in abdominally based free-flap breast reconstruction. 
  • The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. 
  • The effect of system-level access factors on receipt of reconstruction among Latina and white women with DCIS. 
  • The effect of treatment on patient-reported distress after breast cancer diagnosis. 
  • The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. 
  • The effects of NSAIDs on breast cancer prognostic factors. 
  • The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment. 
  • The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. 
  • The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. 
  • The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. 
  • The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. 
  • The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. 
  • The evolving role of sonography in evaluating solid breast masses. 
  • The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. 
  • The genetic attributable risk of breast and ovarian cancer. 
  • The genome's best friend. 
  • The genomic analysis of lactic acidosis and acidosis response in human cancers. 
  • The genomic relationship between primary breast carcinomas and their nodal metastases. 
  • The heritability of breast cancer: a Bayesian correlated frailty model applied to Swedish twins data. 
  • The higher affinity of human type 1 3beta-hydroxysteroid dehydrogenase (3beta-HSD1) for substrate and inhibitor steroids relative to human 3beta-HSD2 is validated in MCF-7 tumor cells and related to subunit interactions. 
  • The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. 
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. 
  • The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. 
  • The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • The impact of health status on physicians' intentions to offer cancer screening to older women. 
  • The impact of lobular histology on breast cancer treatment. 
  • The impact of nodal isolated tumor cells on survival of breast cancer patients. 
  • The impact of obesity on outcomes for patients undergoing mastectomy using the ACS-NSQIP data set. 
  • The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. 
  • The importance of stress management among postresection breast cancer patients. 
  • The incidence and functional consequences of RT-associated cardiac perfusion defects. 
  • The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study. 
  • The influence of cost-effectiveness information on physicians' cancer screening recommendations. 
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. 
  • The influence of increased ambient lighting on mass detection in mammograms. 
  • The influence of uncertainty in illness, stress appraisal, and hope on coping in survivors of breast cancer. 
  • The investigation on the location effect of external markers in respiratory-gated radiotherapy. 
  • The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells. 
  • The medical legal implications of following mammographic breast masses. 
  • The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. 
  • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. 
  • The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. 
  • The natural history of mammographic calcifications subjected to interval follow-up. 
  • The need for epidemiologic studies of in-situ carcinoma of the breast. 
  • The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? 
  • The number of lymph nodes dissected in breast cancer patients influences the accuracy of prognosis. 
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. 
  • The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). 
  • The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. 
  • The promise of group medical visits. 
  • The quantitative potential for breast tomosynthesis imaging. 
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. 
  • The relationship between holding back from communicating about breast concerns and anxiety in the year following breast biopsy. 
  • The role of VEGF in triple-negative breast cancer: where do we go from here? 
  • The role of breast MRI in the management of patients with breast disease. 
  • The role of genetic testing for cancer susceptibility in gynecologic practice. 
  • The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. 
  • The role of lymphoscintigraphy in the management of the patient with breast cancer. 
  • The role of polymorphisms in circadian pathway genes in breast tumorigenesis. 
  • The role of surgery and ablative radiotherapy in oligometastatic breast cancer. 
  • The role of ultrasound-guided fine-needle aspiration of axillary nodes in the staging of breast cancer. 
  • The significance of distant metastases in breast cancer. 
  • The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy. 
  • The significance of the diagnosis of atypia in breast fine-needle aspiration. 
  • The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. 
  • The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. 
  • The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. 
  • The tetraspanin superfamily member NET-6 is a new tumor suppressor gene. 
  • The tumor dormant state. 
  • The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. 
  • The unique DEK oncoprotein in women's health: A potential novel biomarker. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • The use of life expectancy in cancer screening guidelines. Moving with caution from model-based evidence to evidence-based guidelines. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. 
  • The value of mammography screening in women under age 50 years. 
  • Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. 
  • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 
  • Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. 
  • Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment. 
  • Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. 
  • Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer. 
  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. 
  • Timing of weight gain and breast cancer risk. 
  • Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 
  • Tissue transglutaminase expression in human breast cancer. 
  • Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. 
  • Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. 
  • Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. 
  • Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. 
  • Toward population-based indicators of quality end-of-life care: testing stakeholder agreement. 
  • Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. 
  • Towards Prevention of Breast Cancer: What Are the Clinical Challenges? 
  • Towards a genomic-based diagnosis. 
  • Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. 
  • Towards optimized acquisition scheme for multiprojection correlation imaging of breast cancer. 
  • Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors. 
  • Training neural network classifiers for medical decision making: the effects of imbalanced datasets on classification performance. 
  • Trajectories of fatigue in a population-based sample of older adult breast, prostate, and colorectal cancer survivors: an analysis using the SEER-MHOS data resource. 
  • Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors. 
  • Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. 
  • Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. 
  • Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. 
  • Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Trastuzumab emtansine for HER2-positive advanced breast cancer. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 
  • Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. 
  • Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients. 
  • Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases. 
  • Treatment and Outcomes of Women With Large Locally Advanced Breast Cancer. 
  • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 
  • Treatment of complications after breast-conservation therapy. 
  • Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. 
  • Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients. 
  • Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. 
  • Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. 
  • Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Trends in breast cancer stage and mortality in Michigan (1992-2009) by race, socioeconomic status, and area healthcare resources. 
  • Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016. 
  • Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality. 
  • Triaging Patient Scheduling Can Minimize the Risks of Breast Cancer Screening Programs. 
  • Triggers of uncertainty about recurrence and long-term treatment side effects in older African American and Caucasian breast cancer survivors. 
  • Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. 
  • Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. 
  • Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. 
  • Tubular adenomas of the breast: imaging findings with histologic correlation. 
  • Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. 
  • Tumor characteristics in African American and white women. 
  • Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma. 
  • Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. 
  • Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. 
  • Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation. 
  • Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. 
  • Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. 
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. 
  • Type and duration of exogenous hormone use affects breast cancer histology. 
  • Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. 
  • Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. 
  • Uncertainty management intervention for older African American and caucasian long-term breast cancer survivors. 
  • Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors. 
  • Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions. 
  • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 
  • Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. 
  • Undertreatment of obese women receiving breast cancer chemotherapy. 
  • Unique Primary Care Needs of Transgender and Gender Non-Binary People. 
  • Unique features of breast cancer in Taiwan. 
  • Unsupervised anomaly localization in high-resolution breast scans using deep pluralistic image completion. 
  • Up For A Challenge (U4C): Stimulating innovation in breast cancer genetic epidemiology. 
  • Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. 
  • Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. 
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. 
  • Updates on treating ductal carcinoma in situ: what's to know in 2021. 
  • Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. 
  • Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. 
  • Upstage Rate of Complex Sclerosing Lesions/Radial Scars. 
  • Urinary biomarkers of oxidative status in a clinical model of oxidative assault. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Use of Apligraf for a devascularized ulcer secondary to mastectomy and radiation. 
  • Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Use of a multiseparation fiber optic probe for the optical diagnosis of breast cancer. 
  • Use of antibiotics and risk of cancer. 
  • Use of antibiotics and risk of cancer. 
  • Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 
  • Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. 
  • Use of detailed family history data to improve risk prediction,with application to breast cancer screening. 
  • Use of fertility preservation services in female reproductive-aged cancer patients. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
  • Use of multiple media and breast cancer screening: an introduction. 
  • Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. 
  • Use of quinones in brain-tumor therapy: preliminary results of preclinical laboratory investigations. 
  • Use of tablet personal computers for sensitive patient-reported information. 
  • Using Data Price Transparency to Evaluate Autologous and Alloplastic Breast Reconstruction-Does It Tell the Whole (S)tory? 
  • Using Google Trends to analyze patient search interest in implant-based and autologous breast reconstruction. 
  • Using Testlet Response Theory to analyze data from a survey of attitude change among breast cancer survivors. 
  • Using computer-extracted image features for modeling of error-making patterns in detection of mammographic masses among radiology residents. 
  • Using decision lists to construct interpretable and parsimonious treatment regimes. 
  • Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). 
  • Using the Appropriate Formula for QT Measurement Can Save Lives. 
  • Using the BI-RADS lexicon in a restrictive form of double reading as a strategy for minimizing screening mammography recall rates. 
  • Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. 
  • Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study. 
  • Utilization of installation wound vacuum device for breast implant salvage: Approach and results. 
  • Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. 
  • Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. 
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 
  • Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. 
  • Validating the meta-analytical results on MDM2, CASP8, XRCC3 polymorphisms and breast cancer risk: examination of Hardy-Weinberg Equilibrium. 
  • Validation of a breast cancer risk assessment model in women with a positive family history. 
  • Validation of a breast cancer risk prediction model developed for Black women. 
  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). 
  • Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. 
  • Validation of results from knowledge discovery: mass density as a predictor of breast cancer. 
  • Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. 
  • Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. 
  • Validity of breast cancer surgery treatment information in a state-based cancer registry. 
  • Validity of models for predicting BRCA1 and BRCA2 mutations. 
  • Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. 
  • Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. 
  • Variability in the interpretation of screening mammograms by US radiologists. Findings from a national sample. 
  • Variability of Mammographic Imaging Surveillance in Breast Cancer Survivors. 
  • Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. 
  • Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. 
  • Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer. 
  • Variations in cancer care for adolescents and young adults (AYAs) with ductal carcinoma in situ. 
  • Vehicular Traffic-Related Polycyclic Aromatic Hydrocarbon Exposure and Breast Cancer Incidence: The Long Island Breast Cancer Study Project (LIBCSP). 
  • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. 
  • Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. 
  • Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. 
  • Virtual reality as a distraction intervention for women receiving chemotherapy. 
  • Virtual reality intervention for older women with breast cancer. 
  • Virtual reality: a distraction intervention for chemotherapy. 
  • Vitamin E and breast cancer: a review. 
  • Vitamin supplement use and breast cancer in a North Carolina population. 
  • Vitamins E and K induce aryl hydrocarbon hydroxylase activity in human cell cultures. 
  • Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. 
  • Volumetric x-ray coherent scatter imaging of cancer in resected breast tissue: a Monte Carlo study using virtual anthropomorphic phantoms. 
  • Vulnerable And Less Vulnerable Women In High-Deductible Health Plans Experienced Delayed Breast Cancer Care. 
  • WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2: breast. 
  • Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines? 
  • Wavelength optimization for quantitative spectral imaging of breast tumor margins. 
  • Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? 
  • What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS? 
  • What Do Breast Cancer Survivors Expect From Exercise? 
  • What Predicts an Advanced-Stage Diagnosis of Breast Cancer? Sorting Out the Influence of Method of Detection, Access to Care, and Biologic Factors. 
  • What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • What's new in neoadjuvant therapy for breast cancer? 
  • What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. 
  • Which Factors Are Important to Women When Choosing a Breast Reconstruction Surgeon? 
  • Whole Breast Ultrasound: Comparison of the Visibility of Suspicious Lesions with Automated Breast Volumetric Scanning Versus Hand-Held Breast Ultrasound. 
  • Whole-breast radiation therapy: the long and short of it. 
  • Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1. 
  • Whole-genome analysis informs breast cancer response to aromatase inhibition. 
  • Whose Disease Will Recur After Mastectomy for Early Stage, Node-Negative Breast Cancer? A Systematic Review. 
  • Why do breast cancer survivors decline a couple-based intimacy enhancement intervention trial? 
  • Why some women have an optimistic or a pessimistic bias about their breast cancer risk: Experiences, heuristics, and knowledge of risk factors 
  • Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. 
  • Women's experiences with genomic testing for breast cancer recurrence risk. 
  • Women's interest in chemoprevention for breast cancer. 
  • Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. 
  • X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 
  • XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype. 
  • XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. 
  • Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. 
  • Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. 
  • Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. 
  • Yoga Practice Predicts Improvements in Day-to-Day Pain in Women With Metastatic Breast Cancer. 
  • Yoga for women with metastatic breast cancer: results from a pilot study. 
  • Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. 
  • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 
  • Zinc transporter ZIP7 is a novel determinant of ferroptosis. 
  • Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. 
  • [Bilateral breast cancer after Hodgkin disease. Clinical and pathological characteristics and therapeutic possibilities: an analysis of 13 cases]. 
  • [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway]. 
  • [Primary chemotherapy in the treatment of breast cancer]. 
  • [The role of neo-adjuvant chemotherapy in breast cancers]. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
  • [Tumor regression as a prognostic factor in breast cancer]. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
  • gamma-Glutamyl transpeptidase activity in benign and malignant human mammary epithelial lesions. Histochemical evaluation. 
  • iDQC anisotropy map imaging for tumor tissue characterization in vivo. 
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. 
  • mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma. 
  • miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. 
  • p53 alterations in all stages of breast cancer. 
  • p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. 
  • p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. 
  • p53 regulates the expression of the tumor suppressor gene maspin. 
  • p53-dependent induction of heat shock protein 27 (HSP27) expression. 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. 
  • μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hyslop, Terry, Adjunct Professor in the Department of Biostatistics & Bioinformatics, Duke Cancer Institute
  • Jokerst, Nan Marie, J. A. Jones Distinguished Professor of Electrical and Computer Engineering, Nicholas Institute-Energy Initiative
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • Lo, Joseph Yuan-Chieh, Professor in Radiology, Electrical and Computer Engineering
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology
  • Stouder, April Loehmer, Associate Professor in Family Medicine and Community Health, Family Medicine and Community Health, Physician Assistant Program
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Tornai, Martin Paul, Associate Professor of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology